<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005091.pub4" GROUP_ID="NEONATAL" ID="628005012015344265" MERGED_FROM="" MODIFIED="2017-02-06 15:52:12 +0000" MODIFIED_BY="Colleen Ovelman" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.7&lt;/p&gt;&lt;p&gt;sent to Rao for approval Oct 12/05&lt;/p&gt;&lt;p&gt;CL 1/06 (review)&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2017-02-06 10:51:36 -0500" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2017-02-06 10:51:36 -0500" MODIFIED_BY="[Empty name]">
<TITLE>One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates</TITLE>
<CONTACT>
<PERSON ID="D34CC07382E26AA20080535FA1291DC6" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Shripada</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Rao</LAST_NAME>
<SUFFIX/>
<POSITION>Neonatologist</POSITION>
<EMAIL_1>Shripada.Rao@health.wa.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Neonatal Research and Education</DEPARTMENT>
<ORGANISATION>King Edward Memorial Hospital for Women and Princess Margaret Hospital for Children</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Perth, Western Australia</CITY>
<ZIP>6008</ZIP>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>0061 8 9340 8672</PHONE_1>
<PHONE_2/>
<FAX_1>0061 8 9340 8037</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-02-06 10:51:13 -0500" MODIFIED_BY="Colleen Ovelman">
<PERSON ID="D34CC07382E26AA20080535FA1291DC6" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Shripada</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Rao</LAST_NAME>
<SUFFIX/>
<POSITION>Neonatologist</POSITION>
<EMAIL_1>Shripada.Rao@health.wa.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Neonatal Research and Education</DEPARTMENT>
<ORGANISATION>King Edward Memorial Hospital for Women and Princess Margaret Hospital for Children</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Perth, Western Australia</CITY>
<ZIP>6008</ZIP>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>0061 8 9340 8672</PHONE_1>
<PHONE_2/>
<FAX_1>0061 8 9340 8037</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8FB0154082E26AA200D45F89796FED99" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Ravisha</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Srinivasjois</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>srinivasjoisr@ramsayhealth.com.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neonatology and Paediatrics</DEPARTMENT>
<ORGANISATION>University of Western Australia, Joondalup Health Campus</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Joondalup</CITY>
<ZIP/>
<REGION>WA</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61893402222</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1412301452113999634550777636802" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Kwi</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Moon</LAST_NAME>
<SUFFIX/>
<POSITION>Pharmacist</POSITION>
<EMAIL_1>Kwi.Moon@health.wa.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Princess Margaret Hospital for Children</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Perth</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-12-02 00:05:55 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 01/10/05&lt;/p&gt;" NOTES_MODIFIED="2016-12-02 00:05:55 -0500" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="29" MONTH="4" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="8" MONTH="4" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="8" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2017-02-06 10:51:36 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-02-06 10:51:36 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="2" YEAR="2017"/>
<DESCRIPTION>
<P>Added external source of support</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-02-06 10:51:24 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-02-06 10:51:20 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="4" YEAR="2016"/>
<DESCRIPTION>
<P>Search updated in April 2016. There were no new trials that were eligible for inclusion. New excluded trials added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-02-06 10:51:24 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="4" YEAR="2016"/>
<DESCRIPTION>
<P>No change to conclusions of the review.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-11-22 18:44:20 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>Ms Kwi Moon was added to the authorship of this review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-12-16 13:02:49 -0500" MODIFIED_BY="Colleen Ovelman">
<DATE DAY="29" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>This updates the review "One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates" published in the Cochrane Database of Systematic Reviews (<LINK REF="REF-Rao-2006" TYPE="REFERENCE">Rao 2006</LINK>).</P>
<P>Search updated April 2011. No new included trials. New excluded trials added.</P>
<P>No change to conclusion of review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-12-16 13:02:53 -0500" MODIFIED_BY="Colleen Ovelman">
<DATE DAY="29" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>Dr. Ravisha Srinivasjois added to the authorship of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-06-17 11:38:02 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2017-01-24 10:46:39 -0500" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Princess Margaret Hospital for Children, Perth</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The Canberra Hospital</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Royal North Shore Hospital, NSW</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2017-01-24 10:46:39 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-10-31 11:27:48 -0400" MODIFIED_BY="[Empty name]">
<NAME>Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201600005C</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2017-01-24 10:46:39 -0500" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Editorial support for Cochrane Neonatal has been funded with funds from a UK National Institute of Health Research Grant (NIHR) Cochrane Programme Grant (13/89/12). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, or the UK Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-12-05 01:28:39 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-11-22 16:18:19 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-03-09 15:36:12 -0500" MODIFIED_BY="[Empty name]">Gentamicin dosage in neonates</TITLE>
<SUMMARY_BODY MODIFIED="2016-11-22 16:18:19 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Background:</B> Gentamicin is a commonly used antibiotic that is very effective in treating bacterial infections in newborn babies.</P>
<P>
<B>Review question:</B> Whether giving the full dose of gentamicin as a single dose per day is better than giving it as multiple small doses in a day in newborn babies.</P>
<P>
<B>Study characteristics:</B> Eleven scientific studies were analysed to derive the best available evidence. The majority of the studies included newborn babies born after 32 weeks' gestation. The main outcomes assessed were drug levels in the blood and kidney functions. The search was updated to 29 April 2016.</P>
<P>
<B>Key results:</B> Safer and potentially more effective levels of the drug were maintained using a 'one dose per day' treatment schedule. No differences in the risk of adverse effects on the kidney function or hearing were noted between two regimens.<BR/>
</P>
<P>
<B>Quality of evidence:</B> The quality was evidence was considered as moderate because the sample size was relatively small and two of the studies were scientifically less robust.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-11-22 18:57:04 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-11-22 15:55:27 -0500" MODIFIED_BY="[Empty name]">
<P>Animal studies and trials in older children and adults suggest that a 'one dose per day' regimen of gentamicin is superior to a 'multiple doses per day' regimen.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-10-08 12:48:32 -0400" MODIFIED_BY="[Empty name]">
<P>To compare the efficacy and safety of one dose per day compared to multiple doses per day of gentamicin in suspected or proven sepsis in neonates.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-11-22 18:57:04 -0500" MODIFIED_BY="[Empty name]">
<P>Eligible studies were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 3) in the Cochrane Library (searched 8 April 2016), MEDLINE (1966 to 8 April 2016), Embase (1980 to 8 April 2016), and CINAHL (December 1982 to 8 April 2016).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-10-04 09:52:12 -0400" MODIFIED_BY="[Empty name]">
<P>All randomised or quasi-randomised controlled trials comparing one dose per day ('once a day') compared to multiple doses per day ('multiple doses a day') of gentamicin to newborn infants.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-03-01 00:40:12 -0500" MODIFIED_BY="Shripada C Rao">
<P>Data collection and analysis was performed according to the standards of the Cochrane Neonatal Review Group.<BR/>
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-11-22 16:07:56 -0500" MODIFIED_BY="[Empty name]">
<P>Eleven RCTs were included (N = 574) and 28 excluded. All except one study enrolled infants of more than 32 weeks' gestation. Limited information suggested that infants in both 'once a day' as well as 'multiple doses a day' regimens showed adequate clearance of sepsis (typical RR 1.00, 95% CI 0.84 to 1.19; typical RD 0.00, 95% CI &#8722;0.19 to 0.19; 3 trials; N = 37). 'Once a day' gentamicin regimen was associated with fewer failures to attain peak level of at least 5 µg/ml (typical RR 0.22, 95% CI 0.11 to 0.47; typical RD &#8722;0.13, 95% CI &#8722;0.19 to &#8722;0.08; number needed to treat for an additional beneficial outcome (NNTB) = 8; 9 trials; N = 422); and fewer failures to achieve trough levels of 2 µg/ml or less (typical RR 0.38, 95% CI 0.27 to 0.55; typical RD &#8722;0.22, 95% CI &#8722;0.29 to &#8722;0.15; NNTB = 4; 11 trials; N = 503). 'Once a day' gentamicin achieved higher peak levels (MD 2.58, 95% CI 2.26 to 2.89; 10 trials; N = 440) and lower trough levels (MD &#8722;0.57, 95% CI &#8722;0.69 to &#8722;0.44; 10 trials; N = 440) than 'multiple doses a day' regimen. There was no significant difference in ototoxicity between two groups (typical RR 1.69, 95% CI 0.18 to 16.25; typical RD 0.01, 95% CI &#8722;0.04 to 0.05; 5 trials; N = 214). Nephrotoxicity was not noted with either of the treatment regimens. Overall, the quality of evidence was considered to be moderate on GRADE analysis, given the small sample size and unclear/high risk of bias in some of the domains in a few of the included studies.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-11-22 16:08:20 -0500" MODIFIED_BY="[Empty name]">
<P>There is insufficient evidence from the currently available RCTs to conclude whether a 'once a day' or a 'multiple doses a day' regimen of gentamicin is superior in treating proven neonatal sepsis. However, data suggest that pharmacokinetic properties of a 'once a day' gentamicin regimen are superior to a 'multiple doses a day' regimen in that it achieves higher peak levels while avoiding toxic trough levels. There was no change in nephrotoxicity or auditory toxicity. Based on the assessment of pharmacokinetics, a 'once a day regimen' may be superior in treating sepsis in neonates of more than 32 weeks' gestation.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-12-05 01:28:39 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-11-28 15:28:21 -0500" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-11-22 16:19:34 -0500" MODIFIED_BY="[Empty name]">
<P>Gentamicin, an aminoglycoside antibiotic, is widely used in the treatment of suspected or proven bacterial sepsis in newborn infants. It is rapidly bactericidal. Combined with beta-lactam antibiotics, it provides synergistic activity against the most commonly encountered pathogens in the neonatal period (<LINK REF="REF-Chattopadhyay-2002" TYPE="REFERENCE">Chattopadhyay 2002</LINK>). Potential ototoxicity and nephrotoxicity has been linked to the drug levels in plasma. Higher trough concentrations are associated with drug toxicity (<LINK REF="REF-Swan-1997" TYPE="REFERENCE">Swan 1997</LINK>); and lower peak levels are associated with lesser efficacy (<LINK REF="REF-Kovarik-1989" TYPE="REFERENCE">Kovarik 1989</LINK>; <LINK REF="REF-Chambers-2001" TYPE="REFERENCE">Chambers 2001</LINK>). The bactericidal effect of gentamicin is concentration dependent; the higher the concentration, the greater the bactericidal effect. Generally accepted peak concentrations are 5 to 10 µg/ml. It has been suggested that even higher peak levels (e.g. 25 µg per ml) do not increase the risk of toxicity (<LINK REF="REF-Chambers-2001" TYPE="REFERENCE">Chambers 2001</LINK>). It is also suggested that the trough concentrations should be less than 1 to 2 µg/ml to minimise the toxic effects (<LINK REF="REF-Chambers-2001" TYPE="REFERENCE">Chambers 2001</LINK>). Increasing the interval between doses has the potential to maintain maximal bactericidal activity, while minimizing the side effects.</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-11-22 16:29:30 -0500" MODIFIED_BY="[Empty name]">
<P>Several concepts support the benefit of a treatment regime that administers one dose per day ('once a day' dose) of gentamicin (<LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK>).<BR/>
</P>
<OL>
<LI>Gentamicin exhibits a concentration-dependent bactericidal effect in which a positive linear relationship exists between the peak minimum inhibitory concentration (MIC) ratio and bactericidal response.</LI>
<LI>Gentamicin exhibits the post-antibiotic effect (PAE). The PAE is a period during which the antibiotic continues to suppress bacterial growth despite serum concentrations below the MIC (<LINK REF="REF-Kahlmeter-1984" TYPE="REFERENCE">Kahlmeter 1984</LINK>; <LINK REF="REF-Chambers-2001" TYPE="REFERENCE">Chambers 2001</LINK>). A prolonged PAE requires high peak concentrations and is associated with better clinical response. Because a 'once a day' dose produces higher peak drug concentrations, it results in a prolonged PAE (<LINK REF="REF-Craig-1995" TYPE="REFERENCE">Craig 1995</LINK>).</LI>
<LI>One of the first steps in the uptake of aminoglycoside into sites of toxicity is their binding to the brush borders of renal cells and to the cochlea and vestibular membranes. Uptake by these tissues is more efficient with low sustained concentrations compared to high intermittent levels. Animal models suggest that uptake of gentamicin in the renal cortex and perilymph is a saturable process that is relatively unaffected by drug concentration; transient high peak levels do not lead to excessive drug accumulation (<LINK REF="REF-Giuliano-1986" TYPE="REFERENCE">Giuliano 1986</LINK>; <LINK REF="REF-Verpooten-1989" TYPE="REFERENCE">Verpooten 1989</LINK>; <LINK REF="REF-Beaubien-1991" TYPE="REFERENCE">Beaubien 1991</LINK>). 'Once a day' dosing of aminoglycoside has been shown to be less toxic and more efficacious than more frequent dosing in animal models and observational studies in human neonates (<LINK REF="REF-Craig-1995" TYPE="REFERENCE">Craig 1995</LINK>; <LINK REF="REF-Darmstadt-2007" TYPE="REFERENCE">Darmstadt 2007</LINK>; <LINK REF="REF-Darmstadt-2008" TYPE="REFERENCE">Darmstadt 2008</LINK>; <LINK REF="STD-Thingvoll-2008" TYPE="STUDY">Thingvoll 2008</LINK>; <LINK REF="REF-Begg-2009" TYPE="REFERENCE">Begg 2009</LINK>; <LINK REF="STD-Hagen-2009" TYPE="STUDY">Hagen 2009</LINK>).</LI>
<LI>Adaptive resistance is thought to occur after continuous exposure of bacteria to antibiotic concentrations that are less than the MIC (<LINK REF="REF-Lacy-1998" TYPE="REFERENCE">Lacy 1998</LINK>). 'Once a day' dosing may help to avoid the development of resistance by achieving a higher bacterial kill initially, thereby decreasing the length of time viable bacteria are in contact with the drug.</LI>
<LI>Neonates, especially sick infants, have low glomerular filtration rate (<LINK REF="REF-Aperia-1981" TYPE="REFERENCE">Aperia 1981</LINK>; <LINK REF="REF-Vanp_x00e9_e-1993" TYPE="REFERENCE">Vanpée 1993</LINK>; <LINK REF="REF-Sonntag-1996" TYPE="REFERENCE">Sonntag 1996</LINK>; <LINK REF="REF-Gallini-2000" TYPE="REFERENCE">Gallini 2000</LINK>), which leads to slower clearance and higher volume of distribution of drugs like gentamicin (<LINK REF="REF-Nielsen-2009" TYPE="REFERENCE">Nielsen 2009</LINK>). 'Once a day' dosing, by providing more time for clearance, may avoid the toxic effects of gentamicin due to slower clearance (<LINK REF="REF-Begg-2009" TYPE="REFERENCE">Begg 2009</LINK>).</LI>
<LI>Pharmacokinetics of drugs in neonates are unique and greatly influenced by gestational age and birth weight, postnatal age, postconceptional age and renal function (<LINK REF="REF-Nielsen-2009" TYPE="REFERENCE">Nielsen 2009</LINK>; <LINK REF="REF-Pacifici-2009" TYPE="REFERENCE">Pacifici 2009</LINK>; <LINK REF="STD-Serane-2009" TYPE="STUDY">Serane 2009</LINK>). It may be ideal to use customised dosing for infants based on the gentamicin pharmacokinetics in each infant (<LINK REF="REF-Touw-2009" TYPE="REFERENCE">Touw 2009</LINK>). However, this involves frequent measurement of serum gentamicin levels and rewriting of the medication orders with the potential for prescription errors. The majority of the use of gentamicin in the neonatal population is for the treatment of infants with risk factors for sepsis pending culture results for a short period of 48 to 72 hours. If a 'once a day' regimen attains adequate peak levels while avoiding toxic trough levels, then frequent measurement of serum gentamicin levels may not be necessary in these short (72 hour) 'rule out sepsis' courses. This would significantly reduce the hospital cost associated with gentamicin therapy (<LINK REF="REF-Nicolau-1996" TYPE="REFERENCE">Nicolau 1996</LINK>; <LINK REF="REF-Hitt-1997" TYPE="REFERENCE">Hitt 1997</LINK>; <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK>).</LI>
</OL>
</INTERVENTION>
<THEORY MODIFIED="2016-11-28 15:28:21 -0500" MODIFIED_BY="[Empty name]">
<P>Meta analyses of studies in adults have consistently shown that once-daily dosing of aminoglycoside including gentamicin is as effective as multiple daily dosing, with similar or lesser risk of nephrotoxicity and ototoxicity (<LINK REF="REF-Barza-1996" TYPE="REFERENCE">Barza 1996</LINK>; <LINK REF="REF-Munckhof-1996" TYPE="REFERENCE">Munckhof 1996</LINK>; <LINK REF="REF-Ali-1997" TYPE="REFERENCE">Ali 1997</LINK>; <LINK REF="REF-Bailey-1997" TYPE="REFERENCE">Bailey 1997</LINK>; <LINK REF="REF-Hatala-1997" TYPE="REFERENCE">Hatala 1997</LINK>).</P>
<P>A systematic review of similar studies in children and infants concluded that a 'once a day' regimen is more efficacious and has no higher toxicity compared with multiple daily dosing (<LINK REF="REF-Miron-2001" TYPE="REFERENCE">Miron 2001</LINK>). A meta-analysis of extended interval aminoglycoside dosing (the dose is higher and administered less frequently than in a traditional dosing regime) in children reported that an extended-dose aminoglycoside regimen provided similar or potentially improved efficacy and safety, compared to a 'multiple doses a day' regimen (<LINK REF="REF-Contopoulos_x002d_Ioannidis-2004" TYPE="REFERENCE">Contopoulos-Ioannidis 2004</LINK>). A total of 24 studies in paediatric populations up to 20 years of age, including six studies in neonatal populations, were included in their review. Five neonatal studies used gentamicin and one study used amikacin.</P>
<P>Some reports suggest that a 'multiple doses a day' regimen results in subtherapeutic levels and the new practice of extended dosage schedules achieved safe and adequate levels (<LINK REF="REF-Bajaj-2004" TYPE="REFERENCE">Bajaj 2004</LINK>; <LINK REF="REF-Darmstadt-2008" TYPE="REFERENCE">Darmstadt 2008</LINK>; <LINK REF="REF-Begg-2009" TYPE="REFERENCE">Begg 2009</LINK>; <LINK REF="STD-Hagen-2009" TYPE="STUDY">Hagen 2009</LINK>). It has also been suggested that a dose interval of more than 24 hours is less likely to produce toxic trough levels in  preterm neonates (<LINK REF="REF-Langlass-1999" TYPE="REFERENCE">Langlass 1999</LINK>; <LINK REF="STD-Gonzalez-Santacruz-M-2008" TYPE="STUDY">Gonzalez Santacruz M 2008</LINK>; <LINK REF="STD-Thingvoll-2008" TYPE="STUDY">Thingvoll 2008</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-11-22 16:41:40 -0500" MODIFIED_BY="[Empty name]">
<P>Despite this information, the appropriate dose interval for gentamicin in neonates is still a matter of debate. Caution has been expressed against the use of a 'once a day' dose of gentamicin in neonatal infections (<LINK REF="REF-Chambers-2001" TYPE="REFERENCE">Chambers 2001</LINK>). This approach has yet to become standard practice in most paediatric hospitals (<LINK REF="REF-Knoderer-2003" TYPE="REFERENCE">Knoderer 2003</LINK>). A random survey of acute care hospitals in the USA in 1993 found that extended interval aminoglycoside dosing was not practised in neonates, whereas, in 1998, 11.3% of the hospitals were using extended interval dosing (<LINK REF="REF-Chuck-2000" TYPE="REFERENCE">Chuck 2000</LINK>).</P>
<P>In this review, we compared 'one dose per day' versus 'multiple doses per day' of gentamicin in neonates with suspected or proven sepsis.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-11-28 15:37:01 -0500" MODIFIED_BY="[Empty name]">
<P>To compare the efficacy and safety of one dose per day to multiple doses per day of gentamicin in suspected or proven sepsis in neonates.</P>
<P>Subgroup analysis was performed according to:</P>
<OL>
<LI>gestation: less than 32 weeks and 32 weeks or more;</LI>
<LI>suspected or proven sepsis;</LI>
<LI>intramuscular or intravenous administration;</LI>
<LI>use of loading dose.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2016-11-28 15:39:10 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-11-28 15:39:10 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomised and quasi-randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-11-28 15:39:10 -0500" MODIFIED_BY="[Empty name]">
<P>Newborn infants (&#8804; 28 days after birth) with suspected or proven sepsis commenced on gentamicin. Suspected sepsis was defined as any condition in the neonate which led to the commencement of antibiotics. Proven sepsis was defined as a clinical condition necessitating use of antibiotics and presence of positive blood/body fluid or tissue cultures.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-11-22 16:47:27 -0500" MODIFIED_BY="[Empty name]">
<P>One dose per day ('once a day') compared to multiple doses per day ('multiple doses a day') of gentamicin.</P>
<P>Studies comparing extended dose regimens such as dosing once in 36 to 48 hours versus 'once a day' dosing were not included.</P>
<P>Studies comparing regimens with or without loading dosage were not included. If a trial used a loading dose of gentamicin in both groups, it was included.</P>
<P>Since gentamicin is almost always used along with a second antibiotic, studies which used the same second antibiotic in both groups were included.</P>
<P>Studies using gentamicin either intramuscularly or intravenously were included provided both study and control groups were administered gentamicin by the same route.</P>
<P>If a study used a different second antibiotic along with gentamicin in the study and control groups, it was excluded.<BR/>A difference of up to 25% while calculating the total daily dose was allowed between 'once a day' and 'multiple doses a day' regimens.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-11-22 16:53:10 -0500" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-11-22 16:48:03 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Clinical efficacy: clearance of proven sepsis defined as negative blood or other body fluid cultures without the need for a change in antibiotics.</LI>
<LI>Pharmacokinetic efficacy:</LI>
<OL>
<LI>Failure to reach adequate peak levels of at least 5 µg/ml. Peak level was defined as the level measured 0.5 to one hour after administration of any dose of gentamicin on any day during the study period.</LI>
<LI>Failure to avoid toxic trough levels of &gt; 2 µg/ml. The trough level was defined as the level measured within one hour prior to the administration of gentamicin on any day during the study period (except the initial dose).</LI>
</OL>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-11-22 16:53:10 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Ototoxicity (examination could be performed at the end of the study period or before discharge with or without baseline testing):</LI>
<OL>
<LI>Auditory: defined as abnormality in pure tone audiometry or brain-stem evoked auditory response or otoacoustic emission or any other validated hearing test.</LI>
<LI>Vestibular: defined as abnormality in electronystagmography or any other validated vestibular function test.</LI>
</OL>
<LI>Nephrotoxicity (examination could be performed at the end of the study period or before discharge with or without baseline testing):</LI>
<OL>
<LI>Primary: any increase in serum creatinine levels or decrease in creatinine clearance, with thresholds as defined in each study.</LI>
<LI>Secondary: urinary excretion of proteins (retinal binding protein, beta-2 microglobulin, Clara cell protein, microalbumin, N-Acetyl-Beta-D-glucosaminidase, alkaline phosphatase, alanine aminopeptidase, or gamma-glutamyl transferase, cystatin C) or phospholipids.</LI>
</OL>
<LI>Treatment failure: persistent positive blood/body fluid or tissue cultures which lead to any modification of the assigned antibiotic dosing or addition of new antibiotic.</LI>
<LI>Actual peak levels (mean and SD) attained (µg/ml): peak levels were defined as levels measured at 0.5 to 1 hour after a dose of gentamicin.</LI>
<LI>Actual trough levels (mean and SD) attained (µg/ml): trough levels were defined as levels measured within one hour prior to giving any dose of gentamicin (except the initial dose).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-11-22 18:57:56 -0500" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2016-11-22 18:57:56 -0500" MODIFIED_BY="[Empty name]">
<P>We used the standard search strategy of the Cochrane Neonatal Review Group. This included electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 3) in the Cochrane Library (searched 8 April 2016), MEDLINE (1966 to 8 April 2016), Embase (1980 to 8 April 2016) and CINAHL (1982 to 8 April 2016) and previous reviews including cross-references. Abstracts of Pediatric Academic Societies meetings (1995 to 2016) were also searched. MEDLINE and Embase were searched for relevant articles using the following MeSH terms or text words: (Gentamicin/OR aminoglycoside) AND (sepsis OR septicaemia OR septicemia) AND (infant, newborn/OR infant, low birth weight/OR infant, very low birth weight/OR infant, premature/OR Infant, Premature, Diseases) OR (neonate: OR prematur*: OR newborn) AND (clinical trial OR Randomised Controlled Trials). Reference lists of published narrative and systematic reviews were also reviewed. No language restrictions were applied.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-11-22 16:56:31 -0500" MODIFIED_BY="[Empty name]">
<P>We searched clinical trials' registries for ongoing or recently completed trials (<A HREF="http://clinicaltrials.gov">clinicaltrials.gov</A>; <A HREF="http://controlled-trials.com">controlled-trials.com</A>; and <A HREF="http://who.int/ictrp">who.int/ictrp</A>). We also searched reference lists of identified articles.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-11-22 17:20:49 -0500" MODIFIED_BY="[Empty name]">
<P>We used the standard methods of the Cochrane Neonatal Review Group.</P>
<STUDY_SELECTION MODIFIED="2011-08-16 20:42:54 -0400" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed the eligibility of studies for inclusion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-11-22 17:06:58 -0500" MODIFIED_BY="[Empty name]">
<P>We used a data collection form to aid extraction of relevant information and data from each included study. Two review authors extracted the data separately, compared data, and resolved differences by consensus. Any disagreements were resolved by consultation with the third review author.</P>
<P>We contacted the authors of all studies to clarify reported data or provide additional data and information including details of methodology. They were sent a standardised table and asked to provide missing data not included in their article if it was available. <LINK REF="STD-Skopnik-1992" TYPE="STUDY">Skopnik 1992</LINK>, <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK>, <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK>, <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK>, <LINK REF="STD-Chotigeat-2001" TYPE="STUDY">Chotigeat 2001</LINK>, <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK>, <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> and <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK> provided additional information, clarified existing data and also clarified methodology of studies. <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK>, <LINK REF="STD-Solomon-1999" TYPE="STUDY">Solomon 1999</LINK> and <LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK> were contacted initially by e-mail and subsequently by post four weeks later, but did not respond.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-11-22 17:08:03 -0500" MODIFIED_BY="[Empty name]">
<P>The criteria and standard methods of the Cochrane Neonatal Review Group were used to assess the methodological quality of the included trials. Risk of bias of the included trials was evaluated in terms of adequacy of sequence generation, allocation concealment, blinding of parents or caregivers and assessors to intervention, and completeness of follow-up in all randomised individuals. This was defined as 'yes', 'no' or 'not clear' for each category. Differences in opinion were resolved after discussion among all three reviewers. See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the complete 'Risk of bias' tool.<BR/>
</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-11-22 17:08:56 -0500" MODIFIED_BY="[Empty name]">
<P>Statistical analyses were performed using Review Manager software. We analysed categorical data using relative risk (RR), risk difference (RD) and the number needed to treat for an additional beneficial outcome (NNTB). Continuous data were compared using mean difference (MD). We have reported the 95% confidence interval (CI) on all estimates.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-10-04 09:51:17 -0400" MODIFIED_BY="[Empty name]">
<P>If available, we planned to combine results from cluster trials with other trials using generic inverse variance methods.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-11-22 17:09:19 -0500" MODIFIED_BY="[Empty name]">
<P>If participant dropout led to missing data then we planned to conduct an intention-to-treat analysis. We endeavoured to obtain missing data from the trial authors.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-11-22 17:09:26 -0500" MODIFIED_BY="[Empty name]">
<P>Statistical heterogeneity was assessed using the I² statistic. As per the Cochrane guidelines, the I² statistic was interpreted as follows:</P>
<UL>
<LI>0% to 40%: might not be important</LI>
<LI>30% to 60%: may represent moderate heterogeneity</LI>
<LI>50% to 90%: may represent substantial heterogeneity</LI>
<LI>75% to 100%: considerable heterogeneity</LI>
</UL>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-11-22 17:20:49 -0500" MODIFIED_BY="[Empty name]">
<P>Effect size was expressed as relative risk (RR), risk difference (RD) and 95% confidence intervals (CIs) for categorical data, and mean difference (MD) and 95% CI for continuous data. The fixed-effect model was used for meta-analysis. Change scores of auditory and vestibular tests and tests for nephrotoxicity were planned to be meta-analysed separately from the final value scores. For significant differences NNTB based on 1/RD was calculated.</P>
<SUBSECTION>
<HEADING LEVEL="3">Quality of evidence</HEADING>
<P>We assessed the quality of evidence for the main comparison at the outcome level using the GRADE approach (<LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>). This methodological approach considers evidence from randomised controlled trials as high quality that may be downgraded based on consideration of any of five areas: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates and presence of publication bias (<LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>). The GRADE approach results in an assessment of the quality of a body of evidence in one of four grades: 1) High: We are very confident that the true effect lies close to that of the estimate of the effect; 2) Moderate: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; 3) Low: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect; 4) Very Low: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect (<LINK REF="REF-Sch_x00fc_nemann-2013" TYPE="REFERENCE">Schünemann 2013</LINK>).</P>
<P>The review authors independently assessed the quality of the evidence found for outcomes that were considered as critical for clinical decision making. These outcomes included: clearance of proven sepsis, failure to achieve peak level of at least 5 µg/ml, failure to achieve trough levels of 2 µg/ml or less, ototoxicity and nephrotoxicity.</P>
<P>In cases where we considered the risk of bias arising from inadequate concealment of allocation, randomised assignment, complete follow-up or blinded outcome assessment reduced our confidence in the effect estimates, we downgraded the quality of evidence accordingly (<LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>). We evaluated consistency by similarity of point estimates, extent of overlap of confidence intervals and statistical criteria including measurement of heterogeneity (I²). We downgraded the quality of evidence when large and unexplained inconsistency across studies' results was present (i.e. some studies suggest important benefit and others no effect or harm without a clinical explanation) (<LINK REF="REF-Guyatt-2011d" TYPE="REFERENCE">Guyatt 2011d</LINK>). Precision was assessed based on the width of the 95% confidence interval (CI) and by calculating the optimal information size (OIS). If the total number of patients included in the pooled effect estimation was less than the number of patients generated by a conventional sample size calculation for a single adequately powered trial, we considered downrating for imprecision (<LINK REF="REF-Guyatt-2011c" TYPE="REFERENCE">Guyatt 2011c</LINK>). When trials were conducted in populations other than the target population, we downgraded the quality of evidence because of indirectness (<LINK REF="REF-Guyatt-2011e" TYPE="REFERENCE">Guyatt 2011e</LINK>).<BR/>
<BR/>We entered data (i.e. pooled estimates of the effects and corresponding 95% CIs) and explicit judgements for each of the above aspects assessed into the Guideline Development Tool, the software used to create &#8216;Summary of findings&#8217; tables (<LINK REF="REF-GRADEpro" TYPE="REFERENCE">GRADEpro</LINK>). We explained all judgements involving the assessment of the study characteristics described above in footnotes or comments in the &#8216;Summary of findings&#8217; table.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-11-22 17:19:22 -0500" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis was performed according to:<BR/>
</P>
<OL>
<LI>gestation: &lt; 32 weeks and &#8805; 32 weeks;</LI>
<LI>suspected or proven sepsis;</LI>
<LI>intramuscular or intravenous administration;</LI>
<LI>use of loading dose.</LI>
</OL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-11-22 17:20:14 -0500" MODIFIED_BY="[Empty name]">
<P>We planned to conduct sensitivity analyses by excluding studies where trial participants were of extremely low gestation age because these infants may require even further extended dosing intervals for gentamicin (up to 36 to 48 hours).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-11-28 15:38:43 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-11-22 17:26:48 -0500" MODIFIED_BY="[Empty name]">
<P>For a full description of each trial, see the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> section.</P>
<SEARCH_RESULTS MODIFIED="2016-11-21 07:06:21 -0500" MODIFIED_BY="[Empty name]">
<P>Thirty-nine studies were identified as potentially eligible. Twenty-eight were excluded and 11 studies were included in the review; (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-11-22 17:24:57 -0500" MODIFIED_BY="[Empty name]">
<P>Eleven studies were included in this review. All of them were single centre studies. All of the included studies were undertaken since the early 1990s by investigators attached to perinatal centres in North America, India, Thailand, Germany, Spain and Australia. A total of 574 neonates were enrolled in the 11 included trials. <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK>, <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> and <LINK REF="STD-Solomon-1999" TYPE="STUDY">Solomon 1999</LINK> enrolled infants of more than 32 weeks' gestation. <LINK REF="STD-Chotigeat-2001" TYPE="STUDY">Chotigeat 2001</LINK>, <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK>, <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK>, <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK> and <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK> enrolled infants whose gestation was 34 weeks or more. <LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK> enrolled infants whose birth weight was 2500 g or more; and all except three of the neonates enrolled were above 37 weeks' gestation in this study. <LINK REF="STD-Skopnik-1992" TYPE="STUDY">Skopnik 1992</LINK> enrolled only full-term neonates. <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK> enrolled infants whose birth weight was 1200 g or more and was the only study to enrol preterm infants less than 32 weeks' gestational age.</P>
<P>All studies used intravenous infusion of gentamicin except <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK>, where gentamicin was given as a bolus over one minute. <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK> and <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK> used gentamicin both intravenously and intramuscularly. Of the 574 infants enrolled in the trial, only 39 infants had proven sepsis (<LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK>; <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK>; <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK>; <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK>; <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK>). The rest were treated for suspected sepsis. All studies used gentamicin in the dose of 4 to 5 mg/kg/day either as a single dose or as multiple divided doses. The main outcomes assessed were peak and trough levels of gentamicin and renal function. Three studies assessed hearing prior to discharge (<LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK>; <LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK>; <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK>); and one study assessed hearing at one to two months of age (<LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK>). One study assessed the cost of therapy (<LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK>). The details are described in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-11-22 17:26:48 -0500" MODIFIED_BY="[Empty name]">
<P>
<A HREF="http://archie.cochrane.org/sections/documents/view?version=05CA337082E26AA201A2F2795EE81913&amp;format=REVMAN#STD-Skopnik--1995#STD-Skopnik--1995">Skopnik 1995,</A> <LINK REF="STD-Davies-1998" TYPE="STUDY">Davies 1998,</LINK> <LINK REF="STD-Kaspers-1998" TYPE="STUDY">Kaspers 1998,</LINK> <LINK REF="STD-Lundergan-1999" TYPE="STUDY">Lundergan 1999,</LINK> <LINK REF="STD-Stickland-2001" TYPE="STUDY">Stickland 2001</LINK>, <A HREF="http://archie.cochrane.org/sections/documents/view?version=05CA337082E26AA201A2F2795EE81913&amp;format=REVMAN#STD-Alsaedi--2003#STD-Alsaedi--2003">Alsaedi 2003</A>, <LINK REF="STD-Hansen-2003" TYPE="STUDY">Hansen 2003</LINK>, <LINK REF="STD-Lanao-2004" TYPE="STUDY">Lanao 2004</LINK>, <LINK REF="STD-Tantiprabha-2007" TYPE="STUDY">Tantiprabha 2007</LINK>, <LINK REF="STD-Thingvoll-2008" TYPE="STUDY">Thingvoll 2008</LINK>, <LINK REF="STD-Gonzalez-Santacruz-M-2008" TYPE="STUDY">Gonzalez Santacruz M 2008</LINK>, <LINK REF="STD-Serane-2009" TYPE="STUDY">Serane 2009</LINK> and <LINK REF="STD-Hagen-2009" TYPE="STUDY">Hagen 2009</LINK> were excluded because they were not randomised or quasi-randomised controlled trials. <LINK REF="STD-English-2004" TYPE="STUDY">English 2004</LINK> was excluded because a loading dose of 8 mg/kg was used in the 'once a day' gentamicin regimen, whereas no loading dose was used in the 'multiple doses a day' regimen. <LINK REF="STD-Mercado-2004" TYPE="STUDY">Mercado 2004</LINK> and <A HREF="http://archie.cochrane.org/sections/documents/view?version=05CA337082E26AA201A2F2795EE81913&amp;format=REVMAN#STD-Rastogi--2002#STD-Rastogi--2002">Rastogi 2002</A> were excluded because they compared a 'once a day' to a 'once in 48 hours' regimen of gentamicin. <LINK REF="STD-Isemann-1996" TYPE="STUDY">Isemann 1996</LINK> and <LINK REF="STD-Semchuk-1995" TYPE="STUDY">Semchuk 1995</LINK> were excluded because the regimen of loading dose was compared to the regimen of no loading dose of gentamicin. <LINK REF="STD-Tiwari-2009" TYPE="STUDY">Tiwari 2009</LINK> was excluded because relevant data from the neonatal subgroup could not be obtained from the published article. We made three attempts to contact the authors but there was no response.</P>
<P>
<LINK REF="STD-Yeung-2000" TYPE="STUDY">Yeung 2000</LINK>, <LINK REF="STD-Hiltron-2010" TYPE="STUDY">Hiltron 2010</LINK>, <LINK REF="STD-Hossain-2009" TYPE="STUDY">Hossain 2009</LINK>, <LINK REF="STD-Martinkova-2010" TYPE="STUDY">Martinkova 2010</LINK>, <LINK REF="STD-Alshaikh-2012" TYPE="STUDY">Alshaikh 2012</LINK>, <LINK REF="STD-Fjalstad-2014" TYPE="STUDY">Fjalstad 2014</LINK>, <LINK REF="STD-Hoff-2009" TYPE="STUDY">Hoff 2009</LINK>, <LINK REF="STD-Krishnamoorthy-2013" TYPE="STUDY">Krishnamoorthy 2013</LINK> and <LINK REF="STD-Low-2015" TYPE="STUDY">Low 2015</LINK> were also excluded because they were observational studies comparing 'once a day' dosing to different extended dosing regimens.</P>
<P>The details are listed in the table '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-11-22 17:30:10 -0500" MODIFIED_BY="[Empty name]">
<P>The details of risk of bias are described in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<P>Details of the methodological quality of studies are included under the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'.<BR/>
</P>
<ALLOCATION MODIFIED="2016-11-22 17:27:34 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Adequacy of sequence generation</B> was accomplished using computer-generated random numbers in <LINK REF="STD-Skopnik-1992" TYPE="STUDY">Skopnik 1992</LINK>, <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK>, <LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK>, <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK> and <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK>.</P>
<P>
<B>Allocation concealment:</B>
<BR/>Allocation concealment was accomplished in <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK>, <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK>, <LINK REF="STD-Chotigeat-2001" TYPE="STUDY">Chotigeat 2001</LINK>, <LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK>, <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK> and <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK> using sealed envelopes. It was not clear if allocation was concealed in <LINK REF="STD-Solomon-1999" TYPE="STUDY">Solomon 1999</LINK>, <LINK REF="STD-Skopnik-1992" TYPE="STUDY">Skopnik 1992</LINK> and <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK>. Allocation was not concealed in <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> and <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK>. <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> was a quasi-random study with 'once a day' gentamicin being administered in period one (January to March 1998) and 'multiple doses a day' gentamicin being administered in period two (April to June 1998). <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK> was also a quasi-random study (assignment to a particular study group was dependent on the intensive care site, with monthly rotation of dosing regimens).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-11-22 17:28:47 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Blinding of intervention:</B>
<BR/>Blinding of intervention was not done in any of the studies.<BR/>
<BR/>
<B>Blinding of outcome assessment: </B>
<BR/>Outcome assessment was blinded in <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK>, <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK>, <LINK REF="STD-Chotigeat-2001" TYPE="STUDY">Chotigeat 2001</LINK>, <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK>, <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> and <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK>. It was not clear whether outcome assessment was blinded in <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK>, <LINK REF="STD-Solomon-1999" TYPE="STUDY">Solomon 1999</LINK> and <LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK>. It was not blinded in <LINK REF="STD-Skopnik-1992" TYPE="STUDY">Skopnik 1992</LINK> and <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK>.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-11-22 17:29:18 -0500" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Skopnik-1992" TYPE="STUDY">Skopnik 1992</LINK>, <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK>, <LINK REF="STD-Solomon-1999" TYPE="STUDY">Solomon 1999</LINK>, <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK>, <LINK REF="STD-Chotigeat-2001" TYPE="STUDY">Chotigeat 2001</LINK>, <LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK>, <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> and <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK> reported complete follow-up. Follow-up was incomplete in the <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK>, <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK> and <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK> trials, in that more than 10% of enrolled infants did not have outcomes assessed.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-11-22 17:30:10 -0500" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK>, <LINK REF="STD-Chotigeat-2001" TYPE="STUDY">Chotigeat 2001</LINK>, <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK>, <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK>, <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK>, <LINK REF="STD-Skopnik-1992" TYPE="STUDY">Skopnik 1992</LINK>, <LINK REF="STD-Solomon-1999" TYPE="STUDY">Solomon 1999</LINK> and <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK> reported predetermined outcome measures completely. In <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK>, the statistical method to compare serum creatinine on day 0, 3 and 7 was not pre-specified. They have not defined measures to evaluate clinical response within 72 hours of treatment. In <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK>, there was no pre-specified analysis method to measure nephrotoxicity but it was reported that there was no nephrotoxicity in either group at the end of therapy. In <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK>, outcome measures to determine clinical efficacy were not described.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-05-13 13:42:56 -0400" MODIFIED_BY="Colleen Ovelman">
<P>All studies appeared to be free of other bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-11-28 15:38:43 -0500" MODIFIED_BY="[Empty name]">
<P>Eleven studies fulfilled our selection criteria and were included in this review (<LINK REF="STD-Skopnik-1992" TYPE="STUDY">Skopnik 1992</LINK>; <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK>; <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK>; <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK>; <LINK REF="STD-Solomon-1999" TYPE="STUDY">Solomon 1999</LINK>; <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK>; <LINK REF="STD-Chotigeat-2001" TYPE="STUDY">Chotigeat 2001</LINK>; <LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK>; <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK>; <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK>; <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK>). These studies included a total of 574 infants. There was no disagreement regarding inclusion/exclusion of studies, quality assessment or data extraction. Available data were pooled and analysed as listed below.</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Clinical efficacy:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">All studies comparing 'once a day' versus 'multiple doses a day' regimen (Comparison 1)</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Clearance of proven sepsis (Outcome 1.1)</HEADING>
<P>Clearance of proven sepsis was defined as negative blood or other body fluid cultures without the need for changing antibiotic (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). In the <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK> study, both 'once a day' and 'multiple doses a day' regimens achieved clearance of sepsis in all the 29 neonates with proven sepsis. There were two Gram-positive bacterial infections in the <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK> trial: we excluded them from analysis. Only one infant had proven sepsis in the study by <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK>; its outcome was not reported. <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK> reported that all five infants with proven bacteriological sepsis in the 'once a day' gentamicin group responded by clearance of sepsis; and there were no cases of proven sepsis in the 'multiple doses a day' gentamicin group. <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> had one infant in each group with proven sepsis; both infants had clearance of sepsis after institution of antibiotic therapy. Meta-analysis of all studies did not show significant difference between the two groups (typical RR 1.00, 95% CI 0.84 to 1.19; typical RD 0.00, 95% CI &#8722;0.19 to 0.19; 3 trials; N = 37).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pharmacokinetic efficacy:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Failure to attain peak levels of at least 5 µg/ml (Outcome 1.2)</HEADING>
<P>Peak levels of at least 5 µg/ml were considered to be essential to declare that a particular dosing regimen was pharmacologically effective (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). <LINK REF="STD-Skopnik-1992" TYPE="STUDY">Skopnik 1992</LINK>, <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK>, <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK>, <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK>, <LINK REF="STD-Chotigeat-2001" TYPE="STUDY">Chotigeat 2001</LINK>, <LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK>, <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK>, <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> and <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK> reported this outcome. Only <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> reported a statistically significant difference that favoured 'once a day' gentamicin compared to 'multiple doses a day' gentamicin. However, meta-analysis of all the studies showed a statistically significant difference indicating that a 'once a day' regimen is associated with less failures than a 'multiple doses a day' regimen (typical RR 0.22, 95% CI 0.11 to 0.47; typical RD &#8722;0.13, 95% CI &#8722;0.19 to &#8722;0.08; number needed to treat for an additional beneficial outcome (NNTB) = 8; 9 trials; N = 422).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Failure to achieve trough levels of &#8804; 2 µg/ml (Outcome 1.3)</HEADING>
<P>Trough levels of 2 µg/ml or less were considered to be essential to declare that a particular dosing regimen was pharmacologically safe (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). All studies reported this outcome measure. <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK>, <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK>, <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> and <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK> reported a statistically significant difference favouring 'once a day' gentamicin compared to 'multiple doses a day' gentamicin. Meta-analysis of all studies showed a statistically significant difference indicating that 'once a day' gentamicin groups are associated with fewer failures than 'multiple doses a day' regimens (typical RR 0.38, 95% CI 0.27 to 0.55; typical RD &#8722;0.22, 95% CI &#8722;0.29 to &#8722;0.15; NNTB = 4; 11 trials; N = 503).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Ototoxicity (Outcome 1.4)</HEADING>
<UL>
<LI>Auditory: defined as changes in pure tone audiometry or brain-stem evoked auditory responses or otoacoustic emissions or any other validated hearing tests.</LI>
<LI>Vestibular: defined as changes in electronystagmography or any other validated vestibular function test.</LI>
</UL>
<P>Four studies assessed auditory toxicity (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) (<LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK>; <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK>; <LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK>; <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK>). <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK> replied that all infants in both the 'once a day' and 'multiple doses a day' gentamicin groups passed hearing screening tests. <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK> used otoacoustic emission tests both prior to the first dose and after the third dose of gentamicin and did not find evidence of ototoxicity in either group. <LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK> performed hearing screening tests prior to discharge; none of their study infants failed hearing tests. <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK> reported two cases of ototoxicity out of 13 in the 'once a day' group compared to one out of 11 in the 'multiple doses a day' regimen. <LINK REF="STD-Chotigeat-2001" TYPE="STUDY">Chotigeat 2001</LINK> performed the tests for ototoxicity but did not report the results. Meta-analysis of all the studies showed no statistically significant differences in ototoxicity between the two groups (typical RR 1.69, 95% CI 0.18 to 16.25; typical RD 0.01, 95% CI &#8722;0.04 to 0.05; 5 trials; N = 214).</P>
<P>Vestibular toxicity was not tested by any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Nephrotoxicity (Outcome 1.5)</HEADING>
<UL>
<LI>Primary: any increase in serum creatinine levels or decrease in creatinine clearance, with thresholds as defined in each study.</LI>
<LI>Secondary: urinary excretion of proteins (retinal binding protein, beta-2 microglobulin, Clara cell protein, microalbumin, N-Acetyl-Beta-D-glucosaminidase, alkaline phosphatase, alanine aminopeptidase, or gamma-glutamyl transferase) or phospholipids.</LI>
</UL>
<P>
<LINK REF="STD-Skopnik-1992" TYPE="STUDY">Skopnik 1992</LINK>, <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK>, <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK>, <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK>, <LINK REF="STD-Chotigeat-2001" TYPE="STUDY">Chotigeat 2001</LINK>, <LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK>, <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK>, <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> and <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK> reported this outcome (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). <LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK> monitored renal functions by measuring 24-hour urine output on days one, two and three of therapy. Serum electrolytes, blood urea nitrogen and serum creatinine were measured on days two and three of the study. Creatinine clearance and FENa were measured on days two and three of therapy. There were no significant differences between the two groups in all the outcomes measured. <LINK REF="STD-Chotigeat-2001" TYPE="STUDY">Chotigeat 2001</LINK> measured serum creatinine before the beginning of treatment and on the third day and the last day of therapy; there was no significant difference between the two dosage regimens. <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK> measured serum creatinine levels before the beginning of study and subsequently on a daily basis till the completion of treatment; there was no significant difference between the two dosage regimens. <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK> measured serum creatinine and GFR before therapy and on day two or three of therapy. They also measured urinary beta-2 microglobulin levels before and after completion of therapy. There was no significant difference between the two regimens. <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK> measured serum creatinine on day zero, three and seven or the last day of therapy; there was no nephrotoxicity in either group. <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK> measured serum creatinine before and at the end of therapy and found no significant difference in creatinine levels between the two groups. There was no nephrotoxicity in either group. <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> measured serum and urine creatinine and sodium concentrations, urinary lysozyme excretion, glomerular filtration rate and fractional excretion of sodium at 72 to 96 hours of therapy. The values were not significantly different between the two groups; and none of the babies in either group developed nephrotoxicity. <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK> measured the N-Acetyl-Beta-D-glucosaminidase:creatinine ratio as a sensitive indicator of gentamicin-induced nephrotoxicity. First-morning urine within the first two days and on the seventh day of treatment was analyzed. The enzyme levels increased in urine in both groups, more so in the 'multiple doses a day' gentamicin group; however, there was no significant difference. <LINK REF="STD-Skopnik-1992" TYPE="STUDY">Skopnik 1992</LINK> measured urinary aminopeptidase levels as a marker of nephrotoxicity and found that it was increased in both groups in the same pattern during and after discontinuation of gentamicin therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment failure (Outcome 1.6)</HEADING>
<P>Treatment failure was defined as persistent positive blood/body fluid or tissue cultures which led to addition of new antibiotic (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK>, <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK> and <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> reported in total 36 infants with proven sepsis. There were no treatment failures in either the 'once a day' or the 'multiple doses a day' regimens (typical RR 0.0, 95% CI 0.0 to 0.0; typical RD 0.00, 95% CI &#8722;0.19 to 0.19; 3 trials; N = 36).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Actual peak levels (mean and SD) attained (µg/ml) (Outcome 1.7)</HEADING>
<P>Peak levels were defined as levels measured at 0.5 to 1 hour after a dose of gentamicin (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). All studies except <LINK REF="STD-Solomon-1999" TYPE="STUDY">Solomon 1999</LINK> reported this outcome. All studies except <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK> reported a statistically significant difference with higher peak levels attained in the 'once a day' gentamicin regimen. Meta-analysis of the 10 studies involving a total of 440 infants showed a statistically significant difference between the 'once a day' and the 'multiple doses a day' gentamicin regimens with higher peak levels attained in the 'once a day' regimens (MD 2.58, 95% CI 2.26 to 2.89; 10 trials; N = 440). Analysis showed significant heterogeneity and hence should be interpreted with caution.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Actual trough levels (mean and SD) attained (µg/ml) (Outcome 1.8)</HEADING>
<P>Trough levels are defined as levels measured prior to within one hour of giving any dose of gentamicin (except the initial dose) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). All studies except <LINK REF="STD-Solomon-1999" TYPE="STUDY">Solomon 1999</LINK> reported this outcome. All studies except <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK> and <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK> showed statistically significant lower trough levels in the 'once a day' compared to the 'multiple doses a day' gentamicin regimens. Meta-analysis of all the studies showed statistically significant lower trough levels in the 'once a day' regimen versus the 'multiple doses a day' gentamicin regimen (MD &#8722;0.57, 95% CI &#8722;0.69 to &#8722;0.44; 10 trials; N = 440). Analysis showed significant heterogeneity and hence should be interpreted with caution.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis of intramuscular gentamicin</HEADING>
<P>
<LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK> and <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK> used gentamicin intramuscularly in some of their study infants. Separate data for the intramuscular gentamicin was not available from <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK>. <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK> reported the outcomes on four infants with 'once a day' gentamicin, but combined the data for intramuscular and intravenous gentamicin in the 'multiple doses a day' regimen because there was no significant difference in the pharmacokinetic parameters between these groups. The peak gentamicin levels in the 'once a day ' group were significantly higher (P &lt; 0.05) than the 'multiple doses a day' group (11.2 ± 2.0 µg/ml versus 6.6 ± 1.3 µg/ml). The trough levels were significantly lower (P &lt; 0.05) in the 'once a day' group compared to the 'multiple doses a day' group (1.1 ± 0.3 µg/ml versus 1.7 ± 0.5 µg/ml).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis of infants with proven sepsis</HEADING>
<P>As previously noted, very few infants had proven sepsis in the included studies. In the <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK> study, 14 infants (42%) in the 'once a day' group and 15 infants (47%) in the 'multiple doses a day' group had bacteriological sepsis. All infants had clearance of sepsis in both groups. Only one infant had proven sepsis in the study by <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK>; the outcome of this infant was not reported. Two infants had proven Gram-positive sepsis in the study by <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK>, one in each group of the 'once a day' and the 'multiple doses a day' regimen; however, they were excluded from analysis. <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK>'s study reported that all five infants with proven bacteriological sepsis in the 'once a day' gentamicin group responded by clearance of sepsis. There were no cases of proven sepsis in the 'multiple doses a day' gentamicin group. <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> had one infant in each group with proven sepsis; both infants had clearance of sepsis after institution of antibiotic therapy. Meta-analysis of all the studies did not show significant difference between the two groups (typical RD 0.00, 95% CI &#8722;0.19 to 0.19); 3 trials, N = 36). Other outcomes were not reported for this subgroup of infants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis of infants less than 32 weeks' gestation</HEADING>
<P>
<LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK> had seven infants with gestational age less than 32 weeks; all were treated for suspected sepsis. All infants in both groups achieved peak levels of more than 5 µg/ml. Three out of five infants in the 'once a day' group had toxic trough levels of more than 2 µg/ml. Both infants in the 'multiple doses a day' regimen had toxic trough levels of more than 2 µg/ml. No other study enrolled infants of less than 32 weeks' gestation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis of infants in whom loading dose was used in both 'once a day' and 'multiple doses a day' regimen</HEADING>
<P>None of the studies used a loading dose of gentamicin in both the study and control regimens.</P>
<P>Sensitivity analysis by excluding studies where trial participants were of extremely low gestational age could not be done because no studies included such infants.</P>
<P>
<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-12-05 01:28:39 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2016-12-05 01:28:39 -0500" MODIFIED_BY="[Empty name]">
<P>The outcome of 574 neonates from 11 RCTs comparing 'once a day' versus 'multiple doses a day' gentamicin have been reported in this review. For the primary outcome of 'Clearance of proven sepsis', there was no statistically significant difference between the 'once a day' and 'multiple doses a day' regimens of gentamicin. Both treatment regimes were successful at treating infants with proven sepsis. However, the numbers were too small to arrive at definite conclusions. This is as expected because only a very small percentage of neonates with suspected sepsis have a culture-positive infection (<LINK REF="REF-Stoll-1996a" TYPE="REFERENCE">Stoll 1996a</LINK>; <LINK REF="REF-Stoll-1996b" TYPE="REFERENCE">Stoll 1996b</LINK>). For the primary outcomes of 'Failure to attain peak levels of at least 5 µg/ml', and 'Failure to achieve trough levels of &lt; 2 µg/ml', meta-analysis showed a statistically significant difference favouring the 'once a day' gentamicin group. 'Once a day' gentamicin was associated with lower pharmacokinetic failure rates than the 'multiple doses a day' regimen.</P>
<P>For the secondary outcomes of 'Actual peak levels' and 'Actual trough levels' attained, meta-analysis showed that a 'once a day' regimen achieved higher peak levels and lower trough levels compared to a 'multiple doses a day' regimen. However significant heterogeneity was noticed for these two outcomes and therefore these results need to be interpreted with caution. Heterogeneity was explored by re-checking entered data and by excluding individual studies one at a time. Individual trials were studied in detail to explore the cause of heterogeneity. <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK>, <LINK REF="STD-Solomon-1999" TYPE="STUDY">Solomon 1999</LINK> and <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK> enrolled infants of more than 32 weeks' gestation. <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK>, <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK>, <LINK REF="STD-Chotigeat-2001" TYPE="STUDY">Chotigeat 2001</LINK>, <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK> and <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK> enrolled infants of more than 34 weeks' gestation. <LINK REF="STD-Agarwal-2002" TYPE="STUDY">Agarwal 2002</LINK> enrolled infants whose birth weight was 2500 g or above regardless of gestation age. <LINK REF="STD-Skopnik-1992" TYPE="STUDY">Skopnik 1992</LINK> enrolled only full-term neonates. <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK> enrolled infants with birth weight of 1200 g or above. These differences in gestational age and birth weight might have contributed to heterogeneity. All studies used a similar dose of gentamicin (4 to 5 mg/kg/day). Timing of collection of the blood samples for trough levels was the same in all the studies (within 30 minutes of administration of the next dose). Samples for peak levels were collected between 30 to 60 minutes after administration of the dose. The day of therapy on which samples were collected varied between day one to day five; this variation in the day and time of collection of the samples may also have led to heterogeneity. <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK> and <LINK REF="STD-Hayani-1997" TYPE="STUDY">Hayani 1997</LINK> used gentamicin both intramuscularly and intravenously; however, significant heterogeneity still remained even when these two studies were excluded from the meta-analysis. Results remained the same when data were re-analysed using a random-effects model instead of a fixed-effect model.</P>
<P>
<LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK> reported less nephrotoxicity in the 'once a day' gentamicin regimen compared to the 'multiple doses a day' regimen. They measured urinary levels of N-Acetyl-Beta-D-glucosaminidase as the marker of nephrotoxicity. All other seven studies found no difference in the risk of nephrotoxicity between 'once a day' and 'multiple doses a day' gentamicin regimens. In a prospective study, <LINK REF="REF-Nielsen-2009" TYPE="REFERENCE">Nielsen 2009</LINK> evaluated the use of cystatin C along with serum creatinine as a marker of gentamicin clearance and concluded that neither of them correlated with gentamicin clearance. They also concluded that serum creatinine and cystatin C were not predictive markers of renal function in their population set (<LINK REF="REF-Nielsen-2009" TYPE="REFERENCE">Nielsen 2009</LINK>). <LINK REF="REF-Coscia-2008" TYPE="REFERENCE">Coscia 2008</LINK> evaluated the nephrotoxic effects of 'once a day' netilmicin with multiple doses a day in preterm neonates (GA &lt; 37 weeks). The 'once a day' regimen had the same low rates of nephrotoxicity as multiple doses a day, suggesting the possible advantages of the 'once a day' regimen. An RCT in adults measured urinary alanine aminopeptidase (AAP) and N-Acetyl-Beta-D-glucosaminidase (NAG) as markers of nephrotoxicity and found that 'once a day' tobramycin was less nephrotoxic than a 'multiple doses a day' regimen (<LINK REF="REF-Olsen-2004" TYPE="REFERENCE">Olsen 2004</LINK>). Accurately evaluating nephrotoxicity within a neonatal population remains challenging as renal function undergoes rapid maturation in the early weeks after birth and preterm neonates have an initial rise in creatinine (<LINK REF="REF-Blackburn-1994" TYPE="REFERENCE">Blackburn 1994</LINK>; <LINK REF="REF-Kent-2014" TYPE="REFERENCE">Kent 2014</LINK>). The GFR increases rapidly at birth and doubles during the first few weeks after birth (<LINK REF="REF-Blackburn-1994" TYPE="REFERENCE">Blackburn 1994</LINK>). Therefore, using creatinine or GFR to determine aminoglycoside-induced nephrotoxicity may be suboptimal in neonates. As proximal tubule toxicity is the primary mechanism of aminoglycoside nephrotoxicity, urinary biomarkers have been used to measure nephrotoxicity. However, the clinical significance of raised urinary levels associated with normal plasma creatinine levels and normal urine output is unknown (<LINK REF="REF-Kent-2014" TYPE="REFERENCE">Kent 2014</LINK>). <LINK REF="REF-McWilliams-2012" TYPE="REFERENCE">McWilliams 2012</LINK> studied urinary kidney injury molecule 1 (KIM-1) and other biomarkers in neonates receiving gentamicin therapy. Although univariate analysis indicated significant association between aminoglycoside toxicity and urinary KIM-1, urinary N-Acetyl-Beta-D-glycosaminidase, and urinary neutrophil gelatinase-associated lipocalin, in multivariate analysis only urinary KIM-1 elevation was significantly correlated with aminoglycoside treatment, whereas other urinary biomarkers fell out of significance.</P>
<P>Only five studies assessed, and four studies reported, auditory toxicity. No difference was noted between the two groups. Vestibular toxicity was not assessed in any of the studies possibly due to difficulties assessing vestibular function in neonates. Our results are similar to the findings of the systematic review by <LINK REF="REF-Kent-2014" TYPE="REFERENCE">Kent 2014</LINK>, (gentamicin (n) = 577) that found no clear association between peak or trough levels and ototoxicity in neonates. In that review, 22 children (3.8%) were identified as having gentamicin ototoxicity but the authors hypothesized the possibility of a potential overestimation as no repeat tests were performed for verifications following an initial failed hearing screen. <LINK REF="REF-Setiabudy-2013" TYPE="REFERENCE">Setiabudy 2013</LINK> assessed hearing function in neonates with sepsis receiving 24 to 48 hourly aminoglycides using an otoacoustic emission instrument and found no relationship between trough levels and ototoxocity. Similary, <LINK REF="REF-El_x002d_Barbary-2015" TYPE="REFERENCE">El-Barbary 2015</LINK> compared NICU neonates receiving 'once a day' gentamicin to no gentamicin and found that the incidence of hearing loss is comparable in each arm; and longer duration (&gt; 5 days) had no impact on their findings. While these findings are reassuring, it is important to exercise caution and use gentamicin only for the minimum duration possible in neonates. In children, the chances of gentamicin ototoxicity is reported to be greater in those who receive the drug for a longer duration (<LINK REF="REF-Kent-2014" TYPE="REFERENCE">Kent 2014</LINK>). The limitations of the included studies in our review were lack of long-term follow-up testing and failure to take into account other potential risk factors such as concomitant use of ototoxic agents.</P>
<P>A 'once a day' gentamicin regimen requires less pharmacy preparation time and less nursing administration time. <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK> evaluated the cost-effectiveness analysis of 'once a day' gentamicin among neonates and found that a 'once a day' gentamicin regimen was more cost effective than a 'multiple doses a day' regimen. Individualized dosing regimens may be ideal, but are more expensive as they require more frequent measurement of gentamicin levels. Measurement of gentamicin levels is the major contributor to the expense of administering this relatively inexpensive drug (<LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK>; <LINK REF="REF-Bajaj-2004" TYPE="REFERENCE">Bajaj 2004</LINK>). As the great majority of infants treated with gentamicin are treated only for a short time (48 to 72 hours) until deep infection is excluded, this would increase the cost and complexity of their care with no clinical benefit. Therefore, the use of a reliable dosage regimen which then ensures maximum pharmacokinetic efficacy would be beneficial. Although our review was unable to demonstrate superior clinical efficacy of 'once a day' gentamicin, the superiority of 'once a day' gentamicin in achieving less pharmacokinetic failures suggested therapeutic drug monitoring may not be required if gentamicin is used for a short time.</P>
<P>Five out of seven infants of less than 32 weeks' gestation developed toxic trough levels of more than 2 µg/ml. This occurred in both 'once a day' and 'multiple doses a day' regimens indicating that even a 'once a day' regimen may also be toxic in preterm neonates. The possible explanation is that very preterm infants have lower glomerular filtration rates and hence clear gentamicin more slowly than the more mature infants. In a recent retrospective study of 993 newborn infants, more than 20% in a group of preterm infants born between 28 and 31 weeks of gestation receiving 'once a day' gentamicin had an elevated trough level of more than 2 µg/ml; while infants born at less than 28 weeks and more than 35 weeks of gestation who received 36-hourly and 24-hourly gentamicin respectively had very low rates of elevated trough levels. Furthermore, indomethacin co-administration resulted in a significantly higher median gentamicin level compared to infants of similar gestation who did not receive indomethacin (<LINK REF="REF-K_x00f6_nig-2015" TYPE="REFERENCE">König 2015</LINK>). There are several studies evaluating factors influencing gentamicin pharmacokinetics in neonates. <LINK REF="REF-Fuchs-2014" TYPE="REFERENCE">Fuchs 2014</LINK>, an observational study including 3039 neonates, found that body weight and age are the most important factors affecting gentamicin dosage. Another recent population pharmacokinetics study described gentamicin pharmacokinetics in the newborn and, finding creatinine clearance a more important predictor of elimination of gentamicin in preterm infants, proposed 48-hourly dosing for those neonates less than 32 weeks of gestational age (<LINK REF="REF-Garc_x00ed_a-2006" TYPE="REFERENCE">García 2006</LINK>). Evidence is accumulating that an extended dosing regimen of once in 36 to 48 hours may be more suitable for very preterm infants (less than 32 weeks' gestation) (<A HREF="http://archie.cochrane.org/sections/documents/view?version=05CA337082E26AA201A2F2795EE81913&amp;format=REVMAN#STD-Rastogi--2002#STD-Rastogi--2002">Rastogi 2002</A>; <LINK REF="STD-Hansen-2003" TYPE="STUDY">Hansen 2003</LINK>; <LINK REF="STD-Mercado-2004" TYPE="STUDY">Mercado 2004</LINK>; <LINK REF="STD-Thingvoll-2008" TYPE="STUDY">Thingvoll 2008</LINK>; <LINK REF="REF-Garc_x00ed_a-2006" TYPE="REFERENCE">García 2006</LINK>; <LINK REF="REF-K_x00f6_nig-2015" TYPE="REFERENCE">König 2015</LINK>; <LINK REF="REF-Lulic_x002d_Botica-2013" TYPE="REFERENCE">Lulic-Botica 2013</LINK>; <LINK REF="REF-Valitalo-2015" TYPE="REFERENCE">Valitalo 2015</LINK>; <LINK REF="REF-Fullas-2011" TYPE="REFERENCE">Fullas 2011</LINK>). </P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-08-30 22:59:43 -0400" MODIFIED_BY="[Empty name]">
<P>There is some evidence to support the use of 'once a day' dosing of gentamicin in neonates.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-11-22 18:08:43 -0500" MODIFIED_BY="[Empty name]">
<P>Overall, the quality of evidence was considered to be moderate on GRADE analysis, given the small sample size and unclear/high risk of bias in some of the domains in a few of the included studies.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-08-26 01:20:44 -0400" MODIFIED_BY="[Empty name]">
<P>None to our knowledge.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-11-28 15:27:57 -0500" MODIFIED_BY="[Empty name]">
<P>The findings of this review are similar to the meta-analysis in neonates, older children and adults in that 'once a day' gentamicin appears to be comparable in its clinical efficacy, nephrotoxicity and ototoxicity to that of 'multiple doses a day' (<LINK REF="REF-Barza-1996" TYPE="REFERENCE">Barza 1996</LINK>; <LINK REF="REF-Contopoulos_x002d_Ioannidis-2004" TYPE="REFERENCE">Contopoulos-Ioannidis 2004</LINK>; <LINK REF="REF-Bailey-1997" TYPE="REFERENCE">Bailey 1997</LINK>; <LINK REF="REF-Ali-1997" TYPE="REFERENCE">Ali 1997</LINK>; <LINK REF="REF-Munckhof-1996" TYPE="REFERENCE">Munckhof 1996</LINK>; <LINK REF="REF-Nestaas-2005" TYPE="REFERENCE">Nestaas 2005</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-11-22 18:09:39 -0500" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-11-22 18:09:39 -0500" MODIFIED_BY="[Empty name]">
<P>There is insufficient evidence from the currently available RCTs to conclude whether a 'once a day' or a 'multiple doses a day' regimen of gentamicin is superior in treating bacteriologically confirmed neonatal sepsis. However, the pharmacokinetic properties of a 'once a day' gentamicin regimen are superior to 'multiple doses a day' gentamicin in that it achieves higher peak levels while avoiding toxic trough levels. There appear to be no differences in nephrotoxicity or auditory toxicity. Hence a 'once a day' regimen may be superior in treating neonatal sepsis in neonates of more than 32 weeks' gestation.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-03-09 15:40:22 -0500" MODIFIED_BY="[Empty name]">
<P>Studies comparing the 'multiple doses per day' and 'one dose per day' regimens for microbiologically confirmed sepsis requiring prolonged antibiotic therapy need to be done to confirm if the pharmacokinetic benefits translate into clinical efficacy and safety. It is also important to follow such neonates long term to find out the effects on hearing and speech.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-11-22 18:10:58 -0500" MODIFIED_BY="[Empty name]">
<P>We are thankful to the authors of <LINK REF="STD-Krishnan-1997" TYPE="STUDY">Krishnan 1997</LINK>, <LINK REF="STD-de-Alba-Romero-1998" TYPE="STUDY">de Alba Romero 1998</LINK>, <LINK REF="STD-Thureen-1999" TYPE="STUDY">Thureen 1999</LINK>, <LINK REF="STD-Chotigeat-2001" TYPE="STUDY">Chotigeat 2001</LINK>, <LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK>, <LINK REF="STD-Miron-2003" TYPE="STUDY">Miron 2003</LINK>, <LINK REF="STD-Kosalaraksa-2004" TYPE="STUDY">Kosalaraksa 2004</LINK> and <LINK REF="STD-Skopnik-1992" TYPE="STUDY">Skopnik 1992</LINK> for responding to our queries. We are thankful to the lead author of <LINK REF="STD-Gonzalez-Santacruz-M-2008" TYPE="STUDY">Gonzalez Santacruz M 2008</LINK> for providing the translated version of their Spanish article. We are also very thankful to Kathleen Martin, reference librarian at the Canberra Hospital library, Australia for her help in performing the literature search for the initial review (2008). We are very much thankful to Jane Bell, Research Officer, Australasian Coordinating Network for the Cochrane Neonatal Review Group for her valuable help in the literature search for the initial review and suggestions in editing the protocol.</P>
<P>The Cochrane Neonatal Review Group has been funded in part with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN267200603418C. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-10-07 04:23:38 -0400" MODIFIED_BY="[Empty name]">
<P>One of the review authors (RH) for the previous version is also the investigator of one of the included studies (<LINK REF="STD-Hagan-2002" TYPE="STUDY">Hagan 2002</LINK>).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-11-22 18:12:15 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Contributions for the current version of the review (2016)</B>
</P>
<P>Kwi Moon (KM) performed the literature search, identified potential studies (subsequently excluded), reassessed risk of bias of included trials, updated the table of excluded studies, and updated the risk of bias figures, the 'Summary of findings' table and the discussion.</P>
<P>Shripada Rao (SR) conducted an independent literature search, assessed the potential studies for inclusion/exclusion (all subsequently excluded) and edited the new version of the review.</P>
<P>Ravisha Srinivasjois (RS) conducted an independent literature search, assessed the potential studies for inclusion/exclusion (all subsequently excluded) and reviewed the new version of the review.</P>
<P>
<B>Contributions for the previous versions of the review (2006, 2011)</B>
</P>
<P>Shripada Rao (SR) framed the questions for the protocol, wrote the protocol, performed the literature search, selected relevant studies, assessed the methodological quality of studies, checked the data entered into RevMan by Mohamed Ahmed (for the original review), corresponded with authors of the studies to get additional information, wrote the review and compiled other references. SR was also responsible for all the above activities for the updated review.</P>
<P>Mohamed Ahmed (MA) was involved in data entry and analysis.</P>
<P>Ravisha Srinivasjois (RS) performed the literature search and assessed the eligibility of the studies for inclusion/exclusion, and added additional references for the updated review (2011).</P>
<P>Ronald Hagan (RH) revised and edited the drafts of the protocol, provided guidance in selecting outcomes of interest and edited the manuscripts.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-11-22 18:13:15 -0500" MODIFIED_BY="[Empty name]">
<P>We added the methodology and plan for 'Summary of findings' tables and GRADE recommendations, which were not included in the original protocol or in the original review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-02-06 15:52:12 +0000" MODIFIED_BY="Colleen Ovelman">
<STUDIES MODIFIED="2016-11-20 11:23:27 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-11-20 10:21:53 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Agarwal-2002" MODIFIED="2016-11-20 09:59:22 -0500" MODIFIED_BY="[Empty name]" NAME="Agarwal 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-11-20 09:59:22 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agarwal G, Rastogi A, Pyati S, Wilks A, Pildes RS</AU>
<TI>Comparison of once-daily versus twice-daily gentamicin dosing regimens in infants &gt; or = 2500 g</TI>
<SO>Journal of Perinatology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>4</NO>
<PG>268-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386277"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386276"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chotigeat-2001" MODIFIED="2016-11-20 10:02:08 -0500" MODIFIED_BY="[Empty name]" NAME="Chotigeat 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-11-20 10:02:08 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chotigeat U, Narongsanti A, Ayudhya DP</AU>
<TI>Gentamicin in neonatal infection: once versus twice daily dosage</TI>
<SO>Journal of Medical Association of Thailand</SO>
<YR>2001</YR>
<VL>84</VL>
<NO>8</NO>
<PG>1109-15</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386279"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386278"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Alba-Romero-1998" MODIFIED="2016-11-20 10:18:18 -0500" MODIFIED_BY="[Empty name]" NAME="de Alba Romero 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-11-20 10:13:49 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Alba Romero C, Gomez Castillo E, Manzanares Secades C, Rodriguez Lopez J, Arreaza Lopez L, Saenz Valiente P</AU>
<TI>Once daily gentamicin dosing in neonates</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>12</NO>
<PG>1169-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386291"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386290"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Hagan-2002" NAME="Hagan 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hagan R</AU>
<TI>Gentamicin in neonates: single vs multiple doses</TI>
<SO>Abstract book PSANZ 2002</SO>
<YR>2002</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386281"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386280"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayani-1997" MODIFIED="2016-11-20 10:03:13 -0500" MODIFIED_BY="[Empty name]" NAME="Hayani 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-11-20 10:03:13 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayani KC, Hatzopoulos FK, Frank AL, Thummala MR, Hantsch MJ, Schatz BM, et al</AU>
<TI>Pharmacokinetics of once-daily dosing of gentamicin in neonates</TI>
<SO>Journal of Pediatrics</SO>
<YR>1997</YR>
<VL>131</VL>
<NO>1 Pt 1</NO>
<PG>76-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386283"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386282"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosalaraksa-2004" MODIFIED="2016-11-20 10:10:17 -0500" MODIFIED_BY="[Empty name]" NAME="Kosalaraksa 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-11-20 10:10:17 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosalaraksa P, Janthep P, Jirapradittha J, Taksaphan S, Kiatchoosakun P</AU>
<TI>Once versus twice daily dose of gentamicin therapy in Thai neonates</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2004</YR>
<VL>87</VL>
<NO>4</NO>
<PG>372-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386285"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386284"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krishnan-1997" MODIFIED="2016-11-20 10:08:38 -0500" MODIFIED_BY="[Empty name]" NAME="Krishnan 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-11-20 10:08:38 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krishnan L, George SA</AU>
<TI>Gentamicin therapy in preterms: a comparison of two dosage regimens</TI>
<SO>Indian Pediatrics</SO>
<YR>1997</YR>
<VL>34</VL>
<NO>12</NO>
<PG>1075-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386287"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386286"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miron-2003" MODIFIED="2016-11-20 10:11:12 -0500" MODIFIED_BY="[Empty name]" NAME="Miron 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-11-20 10:11:12 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miron D, Steinfeld M, Hasanein J, Felszer C, Reich D</AU>
<TI>Tolerability of once-daily-dosing of intravenous gentamicin in preterm neonates born at 32-37 weeks of gestation</TI>
<SO>Harefuah</SO>
<YR>2003</YR>
<VL>142</VL>
<NO>6</NO>
<PG>413-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386289"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386288"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skopnik-1992" MODIFIED="2016-11-20 10:19:57 -0500" MODIFIED_BY="[Empty name]" NAME="Skopnik 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-11-20 10:19:57 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skopnik H, Wallraf R, Nies B, Troster K, Heimann G</AU>
<TI>Pharmacokinetics and antibacterial activity of daily gentamicin</TI>
<SO>Archives of Diseases in Childhood</SO>
<YR>1992</YR>
<VL>67</VL>
<NO>1 Spec No</NO>
<PG>57-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386293"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386292"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solomon-1999" MODIFIED="2016-11-20 10:20:45 -0500" MODIFIED_BY="[Empty name]" NAME="Solomon 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-11-20 10:20:45 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Solomon R, Kuruvilla KA, Job V, Selvakumar R, Jeyaseelan L, Kanagasabapathy AS, et al</AU>
<TI>Randomized controlled trial of once vs. twice daily gentamicin therapy in newborn</TI>
<SO>Indian Pediatrics</SO>
<YR>1999</YR>
<VL>36</VL>
<NO>2</NO>
<PG>133-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386295"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386294"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thureen-1999" MODIFIED="2016-11-20 10:21:53 -0500" MODIFIED_BY="[Empty name]" NAME="Thureen 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-11-20 10:21:53 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thureen PJ, Reiter PD, Gresores A, Stolpman NM, Kawato K, Hall DM</AU>
<TI>Once- versus twice-daily gentamicin dosing in neonates &gt;=34 weeks' gestation: cost-effectiveness analyses</TI>
<SO>Pediatrics</SO>
<YR>1999</YR>
<VL>103</VL>
<NO>3</NO>
<PG>594-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386297"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386296"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-11-20 11:23:27 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alsaedi--2003" MODIFIED="2016-11-20 10:25:05 -0500" MODIFIED_BY="[Empty name]" NAME="Alsaedi  2003" YEAR="2003">
<REFERENCE MODIFIED="2016-11-20 10:25:05 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alsaedi SA</AU>
<TI>Once daily gentamicin dosing in full term neonates</TI>
<SO>Saudi Medical Journal</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>9</NO>
<PG>978-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386299"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386298"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alshaikh-2012" MODIFIED="2016-11-20 10:25:32 -0500" MODIFIED_BY="[Empty name]" NAME="Alshaikh 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-11-20 10:25:32 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alshaikh B, Dersch-Mills D, Taylor R, Akierman AR, Yusuf K</AU>
<TI>Extended interval dosing of gentamicin in premature neonates &#8804; 2-week gestation</TI>
<SO>Acta Paediatrica</SO>
<YR>2012</YR>
<VL>101</VL>
<NO>11</NO>
<PG>1134-9</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:08:22 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386301"/><IDENTIFIER MODIFIED="2016-01-13 13:08:22 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22897142"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386300"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davies-1998" MODIFIED="2016-11-20 10:27:43 -0500" MODIFIED_BY="[Empty name]" NAME="Davies 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-11-20 10:27:43 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies MW, Cartwright DW</AU>
<TI>Gentamicin dosage intervals in neonates: longer dosage interval--less toxicity</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>1998</YR>
<VL>34</VL>
<NO>6</NO>
<PG>577-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386303"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386302"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-English-2004" MODIFIED="2016-11-20 10:29:28 -0500" MODIFIED_BY="[Empty name]" NAME="English 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-11-20 10:29:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>English M, Mohammed S, Ross A, Ndirangu S, Kokwaro G, Shann F, et al</AU>
<TI>A randomised, controlled trial of once daily and multi-dose daily gentamicin in young Kenyan infants</TI>
<SO>Archives Of Disease in Childhood</SO>
<YR>2004</YR>
<VL>89</VL>
<NO>7</NO>
<PG>665-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386305"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386304"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fjalstad-2014" MODIFIED="2016-11-20 10:31:47 -0500" MODIFIED_BY="[Empty name]" NAME="Fjalstad 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-11-20 10:31:47 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fjalstad JW, Laukli E, van den Anker JN, Klingenberg C</AU>
<TI>High-dose gentamicin in newborn infant: is it safe?</TI>
<SO>European Journal of Paediatrics</SO>
<YR>2014</YR>
<VL>173</VL>
<NO>4</NO>
<PG>489-95</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:08:52 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386307"/><IDENTIFIER MODIFIED="2016-01-13 13:08:52 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10717501"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386306"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalez-Santacruz-M-2008" MODIFIED="2016-11-20 10:34:42 -0500" MODIFIED_BY="[Empty name]" NAME="Gonzalez Santacruz M 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-11-20 10:32:46 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez Santacruz M, Tarazona Fargueta JL, Ferrandis Rodriguez O, Tapia Collados C, Jimenez Cobo B</AU>
<TI>Comparison of two gentamicin dosing schedules in the newborn</TI>
<SO>Anales de pediatría</SO>
<YR>2008</YR>
<VL>68</VL>
<NO>6</NO>
<PG>581-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386309"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-09 15:42:16 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386308"/><IDENTIFIER MODIFIED="2010-03-09 15:42:16 -0500" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=" article published in Spanish, translated to English"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hagen-2009" MODIFIED="2016-11-20 10:35:25 -0500" MODIFIED_BY="[Empty name]" NAME="Hagen 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-11-20 10:35:25 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hagen I, Oymer K</AU>
<TI>Pharmacological differences between once and twice daily gentamicin dosage in newborns with suspected sepsis</TI>
<SO>Pharmacy World and Science</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>1</NO>
<PG>18-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386311"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-09 15:16:18 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386310"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-2003" MODIFIED="2016-11-20 10:40:45 -0500" MODIFIED_BY="[Empty name]" NAME="Hansen 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-11-20 10:40:45 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen A, Forbes P, Arnold A, O'Rourke E</AU>
<TI>Once-daily gentamicin dosing for the preterm and term newborn: proposal for a simple regimen that achieves target levels</TI>
<SO>Journal of Perinatology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>8</NO>
<PG>635-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386313"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386312"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiltron-2010" MODIFIED="2016-01-13 13:10:40 -0500" MODIFIED_BY="[Empty name]" NAME="Hiltron 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-01-13 13:10:40 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiltron AE, Sun Y, Scarpace SB</AU>
<TI>Accuracy of empiric gentamicin dosing guidelines in neonates</TI>
<SO>The Journal of Pediatric Pharmacology and Therapeutics</SO>
<YR>2010</YR>
<VL>15</VL>
<NO>4</NO>
<PG>264-73</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:09:34 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386315"/><IDENTIFIER MODIFIED="2016-01-13 13:09:34 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22477814"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-10-06 21:19:56 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386314"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoff-2009" MODIFIED="2016-01-13 13:10:04 -0500" MODIFIED_BY="[Empty name]" NAME="Hoff 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-01-13 13:10:04 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoff DS, Wilcox RA, Tollefson LM, Lipnik PG, Commers AR, Liu M</AU>
<TI>Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates</TI>
<SO>Pharmacotherapy</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>11</NO>
<PG>1297-305</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:10:04 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386317"/><IDENTIFIER MODIFIED="2016-01-13 13:10:04 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19857147"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386316"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hossain-2009" MODIFIED="2016-11-20 10:43:02 -0500" MODIFIED_BY="[Empty name]" NAME="Hossain 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-11-20 10:43:02 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hossain MM, Chowdhury NA, Shirin MS, Saha SK, Miller-Bell M, Edwards D, et al</AU>
<TI>Simplified dosing of gentamicin for treatment of sepsis in Bangladeshi neonates</TI>
<SO>Journal of Health, Population and Nutrition</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>5</NO>
<PG>640-5</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:10:32 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386319"/><IDENTIFIER MODIFIED="2016-01-13 13:10:32 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19902799"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386318"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isemann-1996" MODIFIED="2016-11-20 10:44:27 -0500" MODIFIED_BY="[Empty name]" NAME="Isemann 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-11-20 10:44:27 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isemann BT, Kotagal UR, Mashni SM, Luckhaupt EJ, Johnson CJ</AU>
<TI>Optimal gentamicin therapy in preterm neonates includes loading doses and early monitoring</TI>
<SO>Therapeutic Drug Monitoring</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>5</NO>
<PG>549-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386321"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386320"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaspers-1998" MODIFIED="2016-11-20 10:46:33 -0500" MODIFIED_BY="[Empty name]" NAME="Kaspers 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-11-20 10:46:33 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaspers GJ, Teunissen PC, Holl H</AU>
<TI>Gentamicin administration in newborns: once daily</TI>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>1998</YR>
<VL>142</VL>
<NO>11</NO>
<PG>583-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386323"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386322"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krishnamoorthy-2013" MODIFIED="2016-11-20 10:54:04 -0500" MODIFIED_BY="[Empty name]" NAME="Krishnamoorthy 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-11-20 10:54:04 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krishnamoorthy SS, Nair A, Furness J, Sanderson J</AU>
<TI>Gentamicin use in neonates: should we have a change of practice?</TI>
<SO>Scottish Medical Journal</SO>
<YR>2013</YR>
<VL>58</VL>
<NO>4</NO>
<PG>241-5</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:11:09 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386325"/><IDENTIFIER MODIFIED="2016-01-13 13:11:09 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24215045"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386324"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lanao-2004" MODIFIED="2016-11-20 10:54:52 -0500" MODIFIED_BY="[Empty name]" NAME="Lanao 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-11-20 10:54:52 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lanao JM, Calvo MV, Mesa JA, Martin-Suarez A, Carbajosa MT, Miguelez F, et al</AU>
<TI>Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2004</YR>
<VL>54</VL>
<NO>1</NO>
<PG>193-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386327"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386326"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Low-2015" MODIFIED="2016-11-20 10:56:25 -0500" MODIFIED_BY="[Empty name]" NAME="Low 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-11-20 10:56:25 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Low YS, Tan SL, Wan AS</AU>
<TI>Extended-interval gentamicin dosing in achieving therapeutic concentrations in Malaysian neonates</TI>
<SO>Journal of Pediatric Pharmacology and Therapeutics</SO>
<YR>2015</YR>
<VL>20</VL>
<NO>2</NO>
<PG>119-25</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:11:34 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386329"/><IDENTIFIER MODIFIED="2016-01-13 13:11:34 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25964729"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386328"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundergan-1999" MODIFIED="2016-11-20 10:57:59 -0500" MODIFIED_BY="[Empty name]" NAME="Lundergan 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-11-20 10:57:59 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lundergan FS, Glasscock GF, Kim EH, Cohen RS</AU>
<TI>Once-daily gentamicin dosing in newborn infants</TI>
<SO>Pediatrics</SO>
<YR>1999</YR>
<VL>103</VL>
<NO>6 Pt 1</NO>
<PG>1228-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386331"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386330"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinkova-2010" MODIFIED="2016-01-13 13:12:04 -0500" MODIFIED_BY="[Empty name]" NAME="Martinkova 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-01-13 13:12:04 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinkova J, Pokorna P, Zahora J, Chladek J, Vobruba V, Selke-Krulichova I, et al</AU>
<TI>Tolerability and outcomes of kinetically guided therapy with gentamicin in critically ill neonates during the first week of life: An open-label, prospective study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2010</YR>
<VL>32</VL>
<NO>14</NO>
<PG>2400-14</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:12:03 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386333"/><IDENTIFIER MODIFIED="2016-01-13 13:12:03 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21353108"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386332"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mercado-2004" MODIFIED="2016-11-20 11:00:52 -0500" MODIFIED_BY="[Empty name]" NAME="Mercado 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-11-20 11:00:52 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mercado MC, Brodsky NL, McGuire MK, Hurt H</AU>
<TI>Extended interval dosing of gentamicin in preterm infants</TI>
<SO>American Journal of Perinatology</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>2</NO>
<PG>73-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386335"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386334"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rastogi--2002" MODIFIED="2016-11-20 11:01:52 -0500" MODIFIED_BY="[Empty name]" NAME="Rastogi  2002" YEAR="2002">
<REFERENCE MODIFIED="2016-11-20 11:01:52 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rastogi A, Agarwal G, Pyati S, Pildes RS</AU>
<TI>Comparison of two gentamicin dosing schedules in very low birth weight infants</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>3</NO>
<PG>234-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386337"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386336"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Semchuk-1995" MODIFIED="2016-11-20 11:14:48 -0500" MODIFIED_BY="[Empty name]" NAME="Semchuk 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-11-20 11:14:48 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Semchuk W, Shevchuk YM, Sankaran K, Wallace SM</AU>
<TI>Prospective, randomized, controlled evaluation of a gentamicin loading dose in neonates</TI>
<SO>Biology of the Neonate</SO>
<YR>1995</YR>
<VL>67</VL>
<NO>1</NO>
<PG>13-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386339"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386338"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serane-2009" MODIFIED="2016-11-20 11:16:18 -0500" MODIFIED_BY="[Empty name]" NAME="Serane 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-11-20 11:16:18 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serane TV, Zengeya S, Penford G, Cooke J, Khanna G, McGregor-Colman E</AU>
<TI>Once daily dose gentamicin in neonates &#8210; is our dosing correct?</TI>
<SO>Acta Paediatrica</SO>
<YR>2009</YR>
<VL>98</VL>
<NO>7</NO>
<PG>1100-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386341"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386340"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skopnik--1995" MODIFIED="2016-11-20 11:17:10 -0500" MODIFIED_BY="[Empty name]" NAME="Skopnik  1995" YEAR="1995">
<REFERENCE MODIFIED="2016-11-20 11:17:10 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skopnik H, Heimann G</AU>
<TI>Once daily aminoglycoside dosing in full term neonates</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>1</NO>
<PG>71-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386343"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386342"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stickland-2001" MODIFIED="2016-11-20 11:19:05 -0500" MODIFIED_BY="[Empty name]" NAME="Stickland 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-11-20 11:19:05 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stickland MD, Kirkpatrick CM, Begg EJ, Duffull SB, Oddie SJ, Darlow BA</AU>
<TI>An extended interval dosing method for gentamicin in neonates</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2001</YR>
<VL>48</VL>
<NO>6</NO>
<PG>887-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386345"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386344"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tantiprabha-2007" MODIFIED="2016-11-20 11:21:26 -0500" MODIFIED_BY="[Empty name]" NAME="Tantiprabha 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-11-20 11:21:26 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tantiprabha W, Juntarakana S, Chotinaruemol S, Rojanasthien N</AU>
<TI>Efficacy and safety of gentamicin by interval and intravenous dosage adjustment based on the gestational age in Thai neonates</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2007</YR>
<VL>90</VL>
<NO>12</NO>
<PG>2601-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386347"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386346"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thingvoll-2008" MODIFIED="2016-11-20 11:22:37 -0500" MODIFIED_BY="[Empty name]" NAME="Thingvoll 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-11-20 11:22:37 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thingvoll ES, Guillet R, Caserta M, Dicenzo R</AU>
<TI>Observational trial of a 48-hour gentamicin dosing regimen derived from Monte Carlo simulations in infants born at less than 28 weeks' gestation</TI>
<SO>Journal of Pediatrics</SO>
<YR>2008</YR>
<VL>153</VL>
<NO>4</NO>
<PG>530-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386349"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386348"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tiwari-2009" MODIFIED="2016-11-20 11:23:27 -0500" MODIFIED_BY="[Empty name]" NAME="Tiwari 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-11-20 11:23:27 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tiwari S, Rehan HS, Chandra J, Mathur NN, Singh V</AU>
<TI>Efficacy and safety of a single daily dose of gentamicin in hospitalized Indian children: a quasi-randomized trial</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2009</YR>
<VL>64</VL>
<NO>5</NO>
<PG>1096-101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386351"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386350"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yeung-2000" MODIFIED="2016-01-13 13:12:57 -0500" MODIFIED_BY="[Empty name]" NAME="Yeung 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-01-13 13:12:57 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeung MY, Smyth JP</AU>
<TI>Targeting gentamicin concentrations in babies: the younger the baby, the larger the loading dose and the longer the dose interval</TI>
<SO>Australian Journal of Hospital Pharmacy</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>3</NO>
<PG>98-101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3386353"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3386352"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-12-05 01:27:21 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-12-05 01:27:21 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ali-1997" MODIFIED="2016-11-28 15:27:57 -0500" MODIFIED_BY="[Empty name]" NAME="Ali 1997" TYPE="JOURNAL_ARTICLE">
<AU>Ali MZ, Goetz MB</AU>
<TI>A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>5</NO>
<PG>796- 809</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:13:25 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-13 13:13:25 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9142772"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aperia-1981" MODIFIED="2016-11-20 11:24:56 -0500" MODIFIED_BY="[Empty name]" NAME="Aperia 1981" TYPE="JOURNAL_ARTICLE">
<AU>Aperia A, Broberger O, Elinder G, Herin P, Zetterstrom R</AU>
<TI>Postnatal development of renal function in pre-term and full-term infants</TI>
<SO>Acta Paediatrica Scandinavia</SO>
<YR>1981</YR>
<VL>70</VL>
<NO>2</NO>
<PG>183-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bailey-1997" MODIFIED="2016-11-20 11:25:33 -0500" MODIFIED_BY="[Empty name]" NAME="Bailey 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC</AU>
<TI>A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>5</NO>
<PG>786-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bajaj-2004" MODIFIED="2016-11-20 11:26:13 -0500" MODIFIED_BY="[Empty name]" NAME="Bajaj 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bajaj M, Palmer K</AU>
<TI>Gentamicin usage in newborns--a simple and practical regime</TI>
<SO>Pharmacy World &amp; Science</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>4</NO>
<PG>242-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barza-1996" MODIFIED="2016-11-20 11:27:39 -0500" MODIFIED_BY="[Empty name]" NAME="Barza 1996" TYPE="JOURNAL_ARTICLE">
<AU>Barza M, Ioannidis JP, Cappelleri JC, Lau J</AU>
<TI>Single or multiple daily doses of aminoglycosides: a meta-analysis</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>312</VL>
<NO>7027</NO>
<PG>338-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beaubien-1991" MODIFIED="2016-11-20 11:28:34 -0500" MODIFIED_BY="[Empty name]" NAME="Beaubien 1991" TYPE="JOURNAL_ARTICLE">
<AU>Beaubien AR, Ormsby E, Bayne A, Carrier K, Crossfield G, Downes M, et al</AU>
<TI>Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1991</YR>
<VL>35</VL>
<NO>6</NO>
<PG>1070-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-2009" MODIFIED="2016-11-20 11:29:17 -0500" MODIFIED_BY="[Empty name]" NAME="Begg 2009" TYPE="JOURNAL_ARTICLE">
<AU>Begg EJ, Vella-Brincat JW, Robertshawe B, McMurtrie MJ, Kirkptrick CM, Darlow B</AU>
<TI>Eight years' experience of an extended-interval dosing protocol for gentamicin in neonates</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2009</YR>
<VL>63</VL>
<NO>5</NO>
<PG>1043-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blackburn-1994" MODIFIED="2016-11-20 11:34:27 -0500" MODIFIED_BY="[Empty name]" NAME="Blackburn 1994" TYPE="JOURNAL_ARTICLE">
<AU>Blackburn ST</AU>
<TI>Renal function in the neonate</TI>
<SO>Journal of Perinatal and Neonatal Nursing</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>1</NO>
<PG>37-47</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:14:21 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-13 13:14:21 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8006805"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chambers-2001" NAME="Chambers 2001" TYPE="BOOK_SECTION">
<AU>Chambers HF</AU>
<TI>The aminoglycosides</TI>
<SO>Goodman and Gillman's The pharmacological basis of therapeutics</SO>
<YR>2001</YR>
<PB>McGraw-Hill Professional</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chattopadhyay-2002" MODIFIED="2016-11-20 11:37:21 -0500" MODIFIED_BY="[Empty name]" NAME="Chattopadhyay 2002" TYPE="JOURNAL_ARTICLE">
<AU>Chattopadhyay B</AU>
<TI>Newborns and gentamicin--how much and how often?</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2002</YR>
<VL>49</VL>
<NO>1</NO>
<PG>13-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chuck-2000" MODIFIED="2016-11-20 11:38:22 -0500" MODIFIED_BY="[Empty name]" NAME="Chuck 2000" TYPE="JOURNAL_ARTICLE">
<AU>Chuck SK, Raber SR, Rodvold KA, Areff D</AU>
<TI>National survey of extended-interval aminoglycoside dosing</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>3</NO>
<PG>433-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Contopoulos_x002d_Ioannidis-2004" MODIFIED="2016-11-20 11:40:03 -0500" MODIFIED_BY="[Empty name]" NAME="Contopoulos-Ioannidis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP</AU>
<TI>Extended-interval aminoglycoside administration for children: a meta-analysis</TI>
<SO>Pediatrics</SO>
<YR>2004</YR>
<VL>114</VL>
<NO>1</NO>
<PG>e111-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coscia-2008" MODIFIED="2016-11-20 11:42:59 -0500" MODIFIED_BY="[Empty name]" NAME="Coscia 2008" TYPE="JOURNAL_ARTICLE">
<AU>Coscia A, Maiorca D, Martano C, Rossi C, Appino I, Cirina P, et al</AU>
<TI>Use of netilmicin once or twice daily in preterm newborns: evaluation of nephrotoxicity by urinary alpha 1-microglobulin and retinol binding protein</TI>
<SO>Journal of Chemotherapy</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>3</NO>
<PG>324-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Craig-1995" NAME="Craig 1995" TYPE="JOURNAL_ARTICLE">
<AU>Craig WA</AU>
<TI>Once-daily versus multiple-daily dosing of aminoglycosides</TI>
<SO>Journal of Chemotherapy</SO>
<YR>1995</YR>
<VL>7 suppl 2</VL>
<PG>47-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Darmstadt-2007" MODIFIED="2016-11-20 11:45:17 -0500" MODIFIED_BY="[Empty name]" NAME="Darmstadt 2007" TYPE="JOURNAL_ARTICLE">
<AU>Darmstadt GL, Hossain MM, Jana AK, Saha SK, Choi Y, Sridhar S, et al</AU>
<TI>Determination of extended-interval gentamicin dosing for neonatal patients in developing countries</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>6</NO>
<PG>501-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Darmstadt-2008" MODIFIED="2010-03-09 15:32:27 -0500" MODIFIED_BY="[Empty name]" NAME="Darmstadt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Darmstadt GL, Miller-Bell M, Batra M, Law P, Law K</AU>
<TI>Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries</TI>
<SO>Journal of Health, Population, and Nutrition</SO>
<YR>2008</YR>
<VL>26</VL>
<PG>163-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Barbary-2015" MODIFIED="2016-11-20 11:47:12 -0500" MODIFIED_BY="[Empty name]" NAME="El-Barbary 2015" TYPE="JOURNAL_ARTICLE">
<AU>El-Barbary MN, Ismail RIH, Ibrahim AAA</AU>
<TI>Gentamicin extended interval regimen and ototoxicity in neonates</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>2015</YR>
<VL>79</VL>
<NO>8</NO>
<PG>1294-8</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:14:50 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-13 13:14:50 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="26071016"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fuchs-2014" MODIFIED="2016-11-20 11:47:57 -0500" MODIFIED_BY="[Empty name]" NAME="Fuchs 2014" TYPE="JOURNAL_ARTICLE">
<AU>Fuchs A, Guidi M, Giannoni E, Werner D, Buclin T, Widmer N, et al</AU>
<TI>Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>2014</YR>
<VL>78</VL>
<NO>5</NO>
<PG>1090-101</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:15:22 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-13 13:15:22 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24938850"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fullas-2011" MODIFIED="2016-01-13 13:15:41 -0500" MODIFIED_BY="[Empty name]" NAME="Fullas 2011" TYPE="JOURNAL_ARTICLE">
<AU>Fullas F, Padomek MT, Thieman CJ, Van Gorp AE</AU>
<TI>Comparative evaluation of six extended-interval gentamicin dosing regimens in premature and full-term neonates</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2011</YR>
<VL>68</VL>
<NO>1</NO>
<PG>52-6</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:15:39 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-13 13:15:39 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21164066"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gallini-2000" MODIFIED="2016-11-20 11:51:18 -0500" MODIFIED_BY="[Empty name]" NAME="Gallini 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gallini F, Maggio L, Romagnoli C, Marrocco G, Tortorolo G</AU>
<TI>Progression of renal function in preterm neonates with gestational age &lt; or = 32 weeks</TI>
<SO>Pediatric Nephrology</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>1-2</NO>
<PG>119-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garc_x00ed_a-2006" MODIFIED="2016-11-20 11:52:04 -0500" MODIFIED_BY="[Empty name]" NAME="García 2006" TYPE="JOURNAL_ARTICLE">
<AU>García B, Barcia E, Pérez F, Molina IT</AU>
<TI>Population pharmacokinetics of gentamicin in premature newborns</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2006</YR>
<VL>58</VL>
<NO>2</NO>
<PG>372-9</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:16:05 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-13 13:16:05 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16782742"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Giuliano-1986" MODIFIED="2016-11-20 11:58:05 -0500" MODIFIED_BY="[Empty name]" NAME="Giuliano 1986" TYPE="JOURNAL_ARTICLE">
<AU>Giuliano RA, Verpooten GA, Verbist L, Wedeen RP, De Broe ME</AU>
<TI>In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1986</YR>
<VL>236</VL>
<NO>2</NO>
<PG>470-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro" MODIFIED="2016-02-25 14:28:02 -0500" MODIFIED_BY="Colleen Ovelman" NAME="GRADEpro" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro</TI>
<TO>www.gradepro.org</TO>
<YR>2014</YR>
<ED>[insert date of use]</ED>
<PB>McMaster University</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2016-02-25 14:04:02 -0500" MODIFIED_BY="Colleen Ovelman" NAME="Guyatt 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al</AU>
<TI>GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-94</PG>
<IDENTIFIERS MODIFIED="2016-02-25 14:03:14 -0500" MODIFIED_BY="Colleen Ovelman"><IDENTIFIER TYPE="PUBMED" VALUE="21195583"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2016-02-25 14:03:58 -0500" MODIFIED_BY="Colleen Ovelman" NAME="Guyatt 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>407-15</PG>
<IDENTIFIERS MODIFIED="2016-02-25 14:03:14 -0500" MODIFIED_BY="Colleen Ovelman"><IDENTIFIER TYPE="PUBMED" VALUE="21247734"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011c" MODIFIED="2016-11-20 11:59:39 -0500" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011c" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al</AU>
<TI>GRADE guidelines: 6. Rating the quality of evidence--imprecision</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1283-93</PG>
<IDENTIFIERS MODIFIED="2016-02-25 14:03:14 -0500" MODIFIED_BY="Colleen Ovelman"><IDENTIFIER TYPE="PUBMED" VALUE="21839614"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011d" MODIFIED="2016-02-25 14:03:49 -0500" MODIFIED_BY="Colleen Ovelman" NAME="Guyatt 2011d" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 7. Rating the quality of evidence--inconsistency</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1294-302</PG>
<IDENTIFIERS MODIFIED="2016-02-25 14:03:14 -0500" MODIFIED_BY="Colleen Ovelman"><IDENTIFIER TYPE="PUBMED" VALUE="21803546"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011e" MODIFIED="2016-02-25 14:03:45 -0500" MODIFIED_BY="Colleen Ovelman" NAME="Guyatt 2011e" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 8. Rating the quality of evidence--indirectness</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1303-10</PG>
<IDENTIFIERS MODIFIED="2016-02-25 14:03:14 -0500" MODIFIED_BY="Colleen Ovelman"><IDENTIFIER TYPE="PUBMED" VALUE="21802903"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hatala-1997" MODIFIED="2016-11-20 12:00:38 -0500" MODIFIED_BY="[Empty name]" NAME="Hatala 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hatala R, Dinh TT, Cook DJ</AU>
<TI>Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>5</NO>
<PG>810-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hitt-1997" MODIFIED="2016-11-20 12:01:16 -0500" MODIFIED_BY="[Empty name]" NAME="Hitt 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hitt CM, Klepser ME, Nightingale CH, Quintiliani R, Nicolau DP</AU>
<TI>Pharmacoeconomic impact of once-daily aminoglycoside administration</TI>
<SO>Pharmacotherapy</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>4</NO>
<PG>810-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kahlmeter-1984" NAME="Kahlmeter 1984" TYPE="JOURNAL_ARTICLE">
<AU>Kahlmeter G, Dahlager JI</AU>
<TI>Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1984</YR>
<VL>13 Suppl A</VL>
<PG>9-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kent-2014" MODIFIED="2016-11-20 12:02:44 -0500" MODIFIED_BY="[Empty name]" NAME="Kent 2014" TYPE="JOURNAL_ARTICLE">
<AU>Kent A, Turner MA, Sharland M, Heath PT</AU>
<TI>Aminoglycoside toxicity in neonates: something to worry about?</TI>
<SO>Expert Review of Anti-infective Therapy</SO>
<YR>2014</YR>
<VL>12</VL>
<NO>3</NO>
<PG>319-31</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:16:33 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-13 13:16:33 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24455994"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Knoderer-2003" MODIFIED="2016-11-20 12:03:19 -0500" MODIFIED_BY="[Empty name]" NAME="Knoderer 2003" TYPE="JOURNAL_ARTICLE">
<AU>Knoderer CA, Everett JA, Buss WF</AU>
<TI>Clinical issues surrounding once-daily aminoglycoside dosing in children</TI>
<SO>Pharmacotherapy</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>1</NO>
<PG>44-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kovarik-1989" MODIFIED="2016-11-20 12:04:16 -0500" MODIFIED_BY="[Empty name]" NAME="Kovarik 1989" TYPE="JOURNAL_ARTICLE">
<AU>Kovarik JM, Hoepelman IM, Verhoef J</AU>
<TI>Once-daily aminoglycoside administration: new strategies for an old drug</TI>
<SO>European Journal of Clinical Microbiology &amp; Infectious Diseases</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>9</NO>
<PG>761-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-K_x00f6_nig-2015" MODIFIED="2016-01-13 13:17:07 -0500" MODIFIED_BY="[Empty name]" NAME="König 2015" TYPE="JOURNAL_ARTICLE">
<AU>König K, Lim A, Miller A, Saker S, Guy KJ, Barfield CP</AU>
<TI>Gentamicin trough levels using a simplified extended-interval dosing regimen in preterm and term newborn</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2014</YR>
<VL>174</VL>
<NO>5</NO>
<PG>669-73</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:17:07 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-13 13:17:07 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25388408"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lacy-1998" MODIFIED="2016-11-20 12:07:18 -0500" MODIFIED_BY="[Empty name]" NAME="Lacy 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R</AU>
<TI>The pharmacodynamics of aminoglycosides</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>1</NO>
<PG>23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Langlass-1999" MODIFIED="2016-11-20 12:07:59 -0500" MODIFIED_BY="[Empty name]" NAME="Langlass 1999" TYPE="JOURNAL_ARTICLE">
<AU>Langlass TM, Mickle TR</AU>
<TI>Standard gentamicin dosage regimen in neonates</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>1999</YR>
<VL>56</VL>
<NO>5</NO>
<PG>440-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lulic_x002d_Botica-2013" MODIFIED="2016-11-20 12:08:35 -0500" MODIFIED_BY="[Empty name]" NAME="Lulic-Botica 2013" TYPE="JOURNAL_ARTICLE">
<AU>Lulic-Botica M, Sheer T, Edwards D, Thomas RL, Natarajan G</AU>
<TI>Impact of small-for-gestation age (SGA) status on gentamicin pharmacokinetics in neonates</TI>
<SO>Pediatric Pharmacology</SO>
<YR>2013</YR>
<VL>54</VL>
<NO>1</NO>
<PG>39-45</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:17:26 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-13 13:17:26 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24122736"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McWilliams-2012" MODIFIED="2016-11-20 12:08:47 -0500" MODIFIED_BY="[Empty name]" NAME="McWilliams 2012" TYPE="JOURNAL_ARTICLE">
<AU>McWilliams SJ, Antoine DJ, Sabbisetti V, Turner MA, Farragher T, Bonventre JV, et al</AU>
<TI>Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study</TI>
<SO>PLoS One</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>8</NO>
<PG>e43809</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:17:53 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-13 13:17:53 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22937100"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miron-2001" MODIFIED="2016-11-20 12:09:31 -0500" MODIFIED_BY="[Empty name]" NAME="Miron 2001" TYPE="JOURNAL_ARTICLE">
<AU>Miron D</AU>
<TI>Once daily dosing of gentamicin in infants and children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>12</NO>
<PG>1169-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Munckhof-1996" MODIFIED="2016-11-20 12:10:51 -0500" MODIFIED_BY="[Empty name]" NAME="Munckhof 1996" TYPE="JOURNAL_ARTICLE">
<AU>Munckhof WJ, Grayson ML, Turnidge JD</AU>
<TI>A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1996</YR>
<VL>37</VL>
<NO>4</NO>
<PG>645-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nestaas-2005" MODIFIED="2016-11-20 12:11:17 -0500" MODIFIED_BY="[Empty name]" NAME="Nestaas 2005" TYPE="JOURNAL_ARTICLE">
<AU>Nestaas E, Bangstad HJ, Sandvik L, Wathne KO</AU>
<TI>Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis</TI>
<SO>Archives of disease in childhood. Fetal and neonatal edition</SO>
<YR>2005</YR>
<VL>90</VL>
<NO>4</NO>
<PG>F294-300</PG>
<IDENTIFIERS MODIFIED="2016-08-30 22:55:01 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="15857879"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nicolau-1996" MODIFIED="2016-11-20 12:12:37 -0500" MODIFIED_BY="[Empty name]" NAME="Nicolau 1996" TYPE="JOURNAL_ARTICLE">
<AU>Nicolau DP, Wu AH, Finocchiaro S, Udeh E, Chow MS, Quintiliani R, et al</AU>
<TI>Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring</TI>
<SO>Therapeutic Drug Monitoring</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>3</NO>
<PG>263-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nielsen-2009" MODIFIED="2016-11-20 12:13:19 -0500" MODIFIED_BY="[Empty name]" NAME="Nielsen 2009" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen EI, Sandström M, Honoré PH, Ewald U, Friberg LE</AU>
<TI>Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study</TI>
<SO>Clinical Pharmacokinetics</SO>
<YR>2009</YR>
<VL>48</VL>
<NO>4</NO>
<PG>253-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olsen-2004" NAME="Olsen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Olsen KM, Rudis MI, Rebuck JA, Hara J, Gelmont D, Mehdian R, Nelson C, Rupp ME</AU>
<TI>Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>32</VL>
<PG>1678-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pacifici-2009" MODIFIED="2010-03-09 15:33:22 -0500" MODIFIED_BY="[Empty name]" NAME="Pacifici 2009" TYPE="JOURNAL_ARTICLE">
<AU>Pacifici GM</AU>
<TI>Clinical pharmacokinetics of aminoglycosides in the neonate: a review</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>2009</YR>
<VL>65</VL>
<PG>419-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2013" MODIFIED="2016-11-20 12:14:00 -0500" MODIFIED_BY="[Empty name]" NAME="Schünemann 2013" TYPE="OTHER">
<AU>Schünemann H, Bro&#380;ek J, Guyatt G, Oxman A, editors; GRADE Working Group</AU>
<TI>GRADE handbook for grading quality of evidence and strength of recommendations</TI>
<SO>Available from www.guidelinedevelopment.org/handbook</SO>
<YR>updated October 2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Setiabudy-2013" MODIFIED="2016-01-13 13:18:24 -0500" MODIFIED_BY="[Empty name]" NAME="Setiabudy 2013" TYPE="JOURNAL_ARTICLE">
<AU>Setiabudy R, Suwento R, Rundjan L, Yasin FH, Louisa M, Dwijayanti A, et al</AU>
<TI>Lack of relationship between the serum concentration of aminoglycosides and ototoxicity in neonates</TI>
<SO>International Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>2013</YR>
<VL>51</VL>
<NO>5</NO>
<PG>401- 6</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:18:24 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-13 13:18:24 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23557866"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sonntag-1996" MODIFIED="2016-11-20 12:14:37 -0500" MODIFIED_BY="[Empty name]" NAME="Sonntag 1996" TYPE="JOURNAL_ARTICLE">
<AU>Sonntag J, Prankel B, Waltz S</AU>
<TI>Serum creatinine concentration, urinary creatinine excretion and creatinine clearance during the first 9 weeks in preterm infants with a birth weight below 1500 g</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>155</VL>
<NO>9</NO>
<PG>815-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stoll-1996a" MODIFIED="2016-11-20 12:15:15 -0500" MODIFIED_BY="[Empty name]" NAME="Stoll 1996a" TYPE="JOURNAL_ARTICLE">
<AU>Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, et al</AU>
<TI>Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network</TI>
<SO>Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>129</VL>
<NO>1</NO>
<PG>72-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stoll-1996b" MODIFIED="2016-11-20 12:16:16 -0500" MODIFIED_BY="[Empty name]" NAME="Stoll 1996b" TYPE="JOURNAL_ARTICLE">
<AU>Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, et al</AU>
<TI>Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network</TI>
<SO>Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>129</VL>
<NO>1</NO>
<PG>63-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swan-1997" MODIFIED="2016-11-20 12:17:03 -0500" MODIFIED_BY="[Empty name]" NAME="Swan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Swan SK</AU>
<TI>Aminoglycoside nephrotoxicity</TI>
<SO>Seminars in Nephrology</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>1</NO>
<PG>27-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Touw-2009" MODIFIED="2016-11-20 12:17:57 -0500" MODIFIED_BY="[Empty name]" NAME="Touw 2009" TYPE="JOURNAL_ARTICLE">
<AU>Touw DJ, Westerman EM, Sprij AJ</AU>
<TI>Therapeutic drug monitoring of aminoglycosides in neonates</TI>
<SO>Clinical Pharmacokinetics</SO>
<YR>2009</YR>
<VL>48</VL>
<NO>2</NO>
<PG>71-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Valitalo-2015" MODIFIED="2016-11-20 12:18:41 -0500" MODIFIED_BY="[Empty name]" NAME="Valitalo 2015" TYPE="JOURNAL_ARTICLE">
<AU>Valitalo PAJ, van den Anker JN, Allegaert K, de Cock RFW, de Hoong M, Simons SHP, et al</AU>
<TI>Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2015</YR>
<VL>70</VL>
<NO>7</NO>
<PG>2074-7</PG>
<IDENTIFIERS MODIFIED="2016-01-13 13:18:57 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-13 13:18:57 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25766737"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vanp_x00e9_e-1993" MODIFIED="2016-11-20 12:19:28 -0500" MODIFIED_BY="[Empty name]" NAME="Vanpée 1993" TYPE="JOURNAL_ARTICLE">
<AU>Vanpée M, Ergander U, Herin P, Aperia A</AU>
<TI>Renal function in sick, very low-birth-weight infants</TI>
<SO>Acta Paediatrica</SO>
<YR>1993</YR>
<VL>82</VL>
<NO>9</NO>
<PG>714-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verpooten-1989" MODIFIED="2016-11-20 12:20:05 -0500" MODIFIED_BY="[Empty name]" NAME="Verpooten 1989" TYPE="JOURNAL_ARTICLE">
<AU>Verpooten GA, Giuliano RA, Verbist L, Eestermans G, De Broe ME</AU>
<TI>Once-daily dosing decreases renal accumulation of gentamicin and netilmicin</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1989</YR>
<VL>45</VL>
<NO>1</NO>
<PG>22-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-11-20 12:21:14 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Rao-2006" MODIFIED="2016-11-20 12:21:14 -0500" MODIFIED_BY="[Empty name]" NAME="Rao 2006" TYPE="COCHRANE_REVIEW">
<AU>Rao SC, Ahmed M, Hagan R</AU>
<TI>One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-03-09 15:27:17 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-03-09 15:27:17 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005091.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-12-05 01:34:05 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-12-05 01:34:05 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-11-21 14:13:23 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Agarwal-2002">
<CHAR_METHODS MODIFIED="2016-11-21 07:25:14 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial; single centre; USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-21 14:00:38 -0500" MODIFIED_BY="[Empty name]">
<P>N = 44. Infants with BW &#8805; 2500 g, age &#8804; 7 days, Apgar scores of &#8805; 5 at 5 minutes, suspected systemic or focal bacterial infection. Exclusion criteria were history of perinatal asphyxia, shock or cardiorespiratory arrest, seizures, anomalies of the kidney or major congenital anomalies incompatible with life and evidence of neuromuscular disorder. 'Once a day' gentamicin: N = 20.<BR/>'Multiple doses a day' gentamicin: N = 21.<BR/>3 infants excluded after enrolment. Mean BW 3302 ± 674 g in 'once a day' vs 3387 ± 526 g in 'Multiple doses a day' gentamicin group. All infants were enrolled within the first 24 h after birth.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-21 14:04:32 -0500" MODIFIED_BY="[Empty name]">
<P>'Once a day' gentamicin group were given gentamicin at 4 mg/kg/dose once every 24 h. 'Multiple doses a day' gentamicin group were given gentamicin at 2.5 mg/kg/dose every 12 h.<BR/>Gentamicin was infused over a period of 30 min with a metered syringe pump using micropore tubing.<BR/>All infants were treated concomitantly with ampicillin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-21 14:13:23 -0500" MODIFIED_BY="[Empty name]">
<P>Blood for peak serum gentamicin was drawn 30 min after completion of the gentamicin infusion; and for trough concentration, 30 min prior to the start of gentamicin infusion. Trough and peak SGCs drawn with the dose at 48 h were considered to reflect steady state. Other outcomes that were measured were urine output, serum creatinine, creatinine clearance and hearing screen test prior to discharge.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-21 15:06:27 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chotigeat-2001">
<CHAR_METHODS MODIFIED="2016-11-21 15:06:27 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial; single centre; Thailand</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-21 14:16:39 -0500" MODIFIED_BY="[Empty name]">
<P>N = 54. Infants with BW &#8805; 2000 g, age &lt; 7 days, gestational age &#8805; 34 weeks, Apgar scores &#8805; 4 at 1 min and 6 at 5 min, suspected or proven bacterial infection. Exclusion criteria were allergy to aminoglycoside, congenital anomalies, renal failure and neuromuscular disorder. 'Once a day' gentamicin: N = 27.<BR/>'Multiple doses a day' gentamicin: N = 27. Mean gestational age in 'once a day' group was 38.44 ± 2.12 weeks vs 38.37 ± 2.12 weeks in 'multiple doses a day' gentamicin group. Mean BW 2924 ± 597 g in 'once a day' vs 2987 ± 656 g in 'multiple doses a day' gentamicin group. Postnatal age in 'once a day' group was 0.94 ± 1.22 days vs 1.43 ± 1.25 days in 'multiple doses a day' gentamicin group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-21 14:17:22 -0500" MODIFIED_BY="[Empty name]">
<P>'Once a day' gentamicin group were given gentamicin at 4 to 5 mg/kg/dose once every 24 h. 'Multiple doses a day' gentamicin group were given gentamicin at 2 to 2.5 mg/kg/dose every 12 h.<BR/>Gentamicin was given as a intravenous infusion over 30 min.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-21 14:19:49 -0500" MODIFIED_BY="[Empty name]">
<P>In 'once a day' gentamicin group blood was drawn for peak serum concentration within 30 min after completion of 3rd dose; and the trough blood sample was drawn within 30 min prior to the 3rd dose. In 'multiple doses a day' gentamicin group blood was drawn for peak serum concentration within 30 minutes after completion of 5th dose; and the trough level blood sample was drawn within 30 min prior to the 5th dose. Other measured outcomes were serum creatinine level on day 1, day 3 and on the day when gentamicin was discontinued.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-16 22:50:23 -0400" MODIFIED_BY="[Empty name]">
<P>Additional information and methodology were clarified by the authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-22 18:15:34 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Alba-Romero-1998">
<CHAR_METHODS MODIFIED="2016-11-21 15:06:37 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial; single centre; Spain<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-21 14:42:28 -0500" MODIFIED_BY="[Empty name]">
<P>N = 80. Inclusion criteria were BW &#8805; 1200 g, with suspected sepsis. Exclusion criteria were known renal impairment (serum creatinine &gt; 1.2 mg/dl), severe neonatal asphyxia and unavailability of blood samples. 'Once a day' gentamicin: N = 33.<BR/>'Multiple doses a day' gentamicin: N = 32. Mean gestational age in 'once a day' gentamicin group was 35.5 ± 3.4 weeks vs 36.2 ± 2.9 weeks in 'multiple doses a day' group. Mean BW in 'once a day' group was 2407 ± 757 g vs 2525 ± 730 g in 'multiple doses a day' group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-21 14:42:46 -0500" MODIFIED_BY="[Empty name]">
<P>'Once a day' gentamicin group were given gentamicin at 5 mg/kg/dose once every 24 h. 'Multiple doses a day' gentamicin group were given gentamicin at 2.5 mg/kg/dose every 12 h. Gentamicin was given as intravenous infusion over 60 min. All patients received ampicillin concomitantly.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-22 18:15:34 -0500" MODIFIED_BY="[Empty name]">
<P>The peak serum gentamicin level was measured 60 min after completion of the infusion on the 4th day of treatment. Trough levels were measured immediately before the administration of the dose on 4th day of treatment. Other outcomes that were measured were urinary N-Acetyl-Beta-D-glucosaminidase:creatinine ratio within the first 2 days and on the 7th day of treatment, serum creatinine on the 4th day of treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-28 21:52:16 -0500" MODIFIED_BY="Shripada C Rao">
<P>Additional information and methodology were clarified by the authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-21 15:09:50 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hagan-2002">
<CHAR_METHODS MODIFIED="2016-11-21 15:06:50 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial; single centre; Australia<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-21 15:09:13 -0500" MODIFIED_BY="[Empty name]">
<P>N = 100. Infants of gestational age more than 33 weeks, age &lt; 7 days and presumed sepsis. Exclusion criteria were BW &lt; 2000 g, history of significant asphyxia, congenital malformation and antenatal diagnosis of renal tract abnormalities. 'Once a day' gentamicin: N = 46.<BR/>'Multiple doses a day' gentamicin : N = 50. Median gestational age in 'once a day' group was 38 (36 to 40 ) weeks vs 39 (35 to 40) weeks in 'multiple doses a day' gentamicin group. Median BW in 'once a day gentamicin' group was 3400 (2614, 3720) g vs 3130 (2560, 3750) g in 'multiple doses a day' gentamicin group. Postnatal age in 'once a day' gentamicin group was 0 (0, 1) vs 1 (1, 2) days in 'multiple doses a day' gentamicin group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>'Once a day' gentamicin group were given gentamicin at 5 mg/kg/dose once every 24 h. 'Multiple doses a day' gentamicin group were given gentamicin at 2.5 mg/kg/dose every 18 h. Gentamicin was given either intravenously or intramuscularly.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-21 15:09:50 -0500" MODIFIED_BY="[Empty name]">
<P>In 'once a day' gentamicin group blood was drawn for peak serum concentration within 30 minutes after completion of 3rd dose; and the trough blood sample was drawn within 30 minutes prior to the 3rd dose. In 'multiple doses a day' gentamicin group blood was drawn for peak serum concentration within 30 minutes after completion of 3rd dose; and the trough level blood sample was drawn within 30 minutes prior to the 3rd dose. Other outcomes that were measured were daily serum creatinine estimation and otoacoustic emission tests 12 h before the first dose and after the third dose of gentamicin.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-28 21:32:26 -0500" MODIFIED_BY="Shripada C Rao">
<P>Additional information and methodology were clarified by the authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-21 15:15:27 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hayani-1997">
<CHAR_METHODS MODIFIED="2016-11-21 15:11:03 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial; single centre, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-21 15:14:32 -0500" MODIFIED_BY="[Empty name]">
<P>N = 31. Infants of gestational age &#8805; 34 weeks, age &#8804; 24 h with suspected sepsis or focal bacterial infection, BW &#8805; 2000 g and Apgar score of 7 or more at 5 min. Exclusion criteria were history of cardiopulmonary arrest, shock, seizures, congenital malformation incompatible with life anomalies of kidney or ear, or presence of neuromuscular disorder. 'Once a day' gentamicin: N = 11.<BR/>'Multiple doses a day' gentamicin: N = 15. Overall mean gestational age was 39.1 (35 to 41) weeks. Mean BW was 3200 (2100 to 4500) g .</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-21 15:14:42 -0500" MODIFIED_BY="[Empty name]">
<P>'Once a day' gentamicin group were given gentamicin at 5 mg/kg/dose once every 24 h. 'Multiple doses a day' gentamicin group were given gentamicin at 2.5 mg/kg/dose every 12 h. Gentamicin was given either intravenously or intramuscularly.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-21 15:15:27 -0500" MODIFIED_BY="[Empty name]">
<P>Serum gentamicin levels were measured on day 3 of life. Peak serum gentamicin levels were obtained 30 minutes after the end of intravenous dose or 60 minutes after an intramuscular dose. Trough levels were obtained 30 minutes before the dose. Other outcomes measured were urine output, serum creatinine, serum electrolytes, blood urea nitrogen, urine sodium, urine creatinine, urine beta-2 microglobulin levels and glomerular filtration rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-21 15:30:33 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kosalaraksa-2004">
<CHAR_METHODS MODIFIED="2016-11-21 15:27:40 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial; single centre; Thailand.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-21 15:30:33 -0500" MODIFIED_BY="[Empty name]">
<P>N = 64. Inclusion criteria were BW &#8805; 2000 g, age &#8804; 7 days, Apgar score of &gt; 6 at 5 min and suspected sepsis. Exclusion criteria were history of perinatal asphyxia, shock, cardiopulmonary arrest, seizure, neuromuscular disorder or anomalies of kidney or ear. 'Once a day' gentamicin: N = 33.<BR/>'Multiple doses a day' gentamicin: N = 31. Mean gestational age in 'once a day' gentamicin group was 38.4 ± 1.8 weeks vs 38.6 ± 2.1 weeks in 'multiple doses a day' group. Mean BW in 'once a day' group was 3044 ± 475 g vs 3036 ± 497 g in 'multiple doses a day' group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-21 15:28:49 -0500" MODIFIED_BY="[Empty name]">
<P>'Once a day' gentamicin group were given gentamicin at 5 mg/kg/dose once every 24 h. 'Multiple doses a day' gentamicin group were given gentamicin at 2.5 mg/kg/dose every 12 h. Gentamicin was given as intravenous infusion over 60 min.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-21 15:29:26 -0500" MODIFIED_BY="[Empty name]">
<P>The peak serum gentamicin level was measured 30 min after infusion (after the 3rd dose in 'once a day' group and the 6th dose in the 'multiple doses a day' group. Trough levels were measured immediately before the 4th dose in 'once a day' group and the 7th dose in the 'multiple doses a day' group. Other outcomes that were measured were urine output, serum creatinine on day 0, 3 and 7 or on the discontinuation day.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-28 21:32:17 -0500" MODIFIED_BY="Shripada C Rao">
<P>Additional information and methodology were clarified by the authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-21 15:32:39 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krishnan-1997">
<CHAR_METHODS MODIFIED="2016-11-21 15:30:47 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial; single centre; India<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-21 15:31:53 -0500" MODIFIED_BY="[Empty name]">
<P>N = 18. Inclusion criteria were neonates requiring gentamicin therapy as per unit protocol, 32 to 36 weeks' gestation, &lt; 96 h of age, and serum creatinine &lt; 1 mg/dl. 'Once a day' gentamicin: N = 9.<BR/>Multiple doses a day' gentamicin: N = 9. Mean gestational age was 34.1 ± 1.5 weeks in 'once a day' gentamicin group and 34.0 ± 1.9 weeks in 'multiple doses a day' group. Mean BW in 'once a day' group was 1940 ± 510 g and 1739 ± 527 g in 'multiple doses a day' group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-21 15:32:21 -0500" MODIFIED_BY="[Empty name]">
<P>'Once a day' gentamicin group were given gentamicin at 4 mg/kg/dose once every 24 h. 'Multiple doses a day' gentamicin group were given gentamicin at 2.5 mg/kg/dose every 12 h. Gentamicin was given as 1-min bolus intravenously followed by normal saline flush of 0.5 ml.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-21 15:32:39 -0500" MODIFIED_BY="[Empty name]">
<P>Peak levels were collected 1 hour after the first dose and the dose given at 48 h. Trough levels were collected just prior to the dose of gentamicin due at 48 h after the start of the therapy. Other outcomes measured were serum creatinine.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-28 21:32:10 -0500" MODIFIED_BY="Shripada C Rao">
<P>Additional information and methodology were clarified by the authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-05 01:32:30 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miron-2003">
<CHAR_METHODS MODIFIED="2016-12-05 01:32:30 -0500" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised controlled trial; single centre; Israel. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-21 15:35:47 -0500" MODIFIED_BY="[Empty name]">
<P>N = 35. Inclusion criteria were BW &#8805; 1500 g, age &#8804; 24 h, gestational age 32 to 37 weeks and suspected sepsis. Exclusion criteria were shock, impaired renal function and known kidney, ear or heart malformations and metabolic disease. 'Once a day' gentamicin: N = 17.<BR/>'Multiple doses a day' gentamicin: N = 18.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>'Once a day' gentamicin group were given gentamicin at 5 mg/kg/dose once every 24 h. 'Multiple doses a day' gentamicin group were given gentamicin at 2.5 mg/kg/dose every 12 h.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-21 15:49:42 -0500" MODIFIED_BY="[Empty name]">
<P>The serum gentamicin levels were measured at 72 h to 96 h of therapy. The peak serum gentamicin level was measured 30 minutes after infusion. Trough levels were measured 30 min before the next dose. Other outcomes that were measured were serum and urine creatinine and sodium concentrations, urinary lysozyme excretion, glomerular filtration rate and fractional excretion of sodium at 72 h to 96 h of therapy. Pure tone audiometric evaluation was performed at 1 to 2 months of age. Brainstem-evoked response audiometry was performed if there was suspicion on pure tone audiometry.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Additional information and methodology were clarified by the authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-21 15:53:27 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Skopnik-1992">
<CHAR_METHODS MODIFIED="2016-11-21 15:33:32 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial; single centre; Germany<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-21 15:52:15 -0500" MODIFIED_BY="[Empty name]">
<P>N = 20. Inclusion criteria were neonates with pneumonia, meconium aspiration, suspected bacterial sepsis, and premature rupture of membranes &gt; 36 h before delivery. Exclusion criteria were gestational age &lt; 37 weeks, BW &lt; 2500 g, Apgar score of &#8804; 4 at 1 minute and &#8804; 6 at 5 minutes, serum creatinine &gt; 85 micromol/l and those requiring diuretics during the course of treatment and those who were exposed to aminoglycoside prenatally. 'Once a day' gentamicin: N = 10.<BR/>'Multiple doses a day' gentamicin: N = 10. Mean gestational age in 'once a day' gentamicin group was 39.5 ± 1.4 weeks vs 40.3 ± 0.8 weeks in 'multiple doses a day' group. Mean BW in 'once a day' group was 3300 ± 600 g vs 3800 ± 600 g in 'multiple doses a day' group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-21 15:52:43 -0500" MODIFIED_BY="[Empty name]">
<P>'Once a day' gentamicin group were given gentamicin at 4 mg/kg/dose once every 24 h. 'Multiple doses a day' gentamicin group were given gentamicin at 2 mg/kg/dose every 12 h. Gentamicin was given as intravenous infusion over 30 min. All infants were treated with ampicillin concomitantly.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-21 15:53:27 -0500" MODIFIED_BY="[Empty name]">
<P>The pharmacokinetic profile of gentamicin was determined on the fourth day of treatment. Outcomes measured were peak levels, trough levels and area under the concentration time curves, urinary excretion of alanine aminopeptidase as a marker of nephrotoxicity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-28 21:33:00 -0500" MODIFIED_BY="Shripada C Rao">
<P>Additional information and methodology were clarified by the authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-21 15:55:11 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Solomon-1999">
<CHAR_METHODS MODIFIED="2016-11-21 15:54:03 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial; single centre; India</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-21 15:54:43 -0500" MODIFIED_BY="[Empty name]">
<P>N = 73. Inclusion criteria were gestational age &#8805; 32 weeks, with suspected or confirmed sepsis. 48 term and 25 preterm infants were included. 'Once a day' gentamicin: N = 37.<BR/>'Multiple doses a day' gentamicin: N = 36. Among preterm infants, the mean gestational age in 'once a day' gentamicin group was 34.2 ± 1.1 weeks vs 33.0 ± 0.7 weeks in 'multiple doses a day' group. Mean BW in 'once a day' group was 1919 ± 255 g vs 1830 ± 184 g in 'multiple doses a day' group. Among term infants, the mean gestational age in 'once a day' group was 39.2 ± 1.4 weeks vs 39 ± 1.3 weeks in 'multiple doses a day' group. Mean BW in 'once a day' group was 2935 ± 552 g vs 2968 ± 613 g in 'multiple doses a day' group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-21 15:54:58 -0500" MODIFIED_BY="[Empty name]">
<P>'Once a day' gentamicin group were given gentamicin at 4 mg/kg/dose once every 24 h. 'Multiple doses a day' gentamicin group were given gentamicin at 2.5 mg/kg/dose every 12 h. Gentamicin was given as intravenous infusion over 30 min followed by normal saline flush.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-21 15:55:11 -0500" MODIFIED_BY="[Empty name]">
<P>The peak serum gentamicin level was measured 60 min after completion of the infusion of the 2nd dose of gentamicin. Trough levels were measured 30 min before the administration of the 2nd dose of gentamicin.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-21 15:57:16 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thureen-1999">
<CHAR_METHODS MODIFIED="2016-11-21 15:55:46 -0500" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised controlled trial; single centre; USA. Dose schedules were rotated on a monthly basis.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-21 15:56:25 -0500" MODIFIED_BY="[Empty name]">
<P>N = 55. Inclusion criteria were gestational age &#8805; 34 weeks, postnatal age &lt; 7 days, Apgar scores of &gt; 4 at 1 minute and &gt; 6 at 5 minutes respectively, urine output &gt; 0.5 ml/kg/hour in the first 24 h of life or &gt; 1 ml/kg/h in the second 24 h of life and absence of inotropic support. 'Once a day' gentamicin: N = 27.<BR/>'Multiple doses a day' gentamicin: N = 28. Mean gestational age in 'once a day' gentamicin group was 37.8 ± 2.1 weeks vs 36.9 ± 2.6 weeks in 'multiple doses a day' group. Mean BW in 'once a day' group was 2831 ± 613 g vs 2795 ± 714 g in 'multiple doses a day' group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-21 15:56:36 -0500" MODIFIED_BY="[Empty name]">
<P>'Once a day' gentamicin group were given gentamicin at 4 mg/kg/dose once every 24 h. 'Multiple doses a day' gentamicin group were given gentamicin at 2.5 mg/kg/dose every 12 h . Gentamicin was given as intravenous infusion over 30 min. All patients received ampicillin concomitantly.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-21 15:57:16 -0500" MODIFIED_BY="[Empty name]">
<P>The peak serum gentamicin level was measured 30 min after completion of the infusion on day three of therapy (fifth dose of 'multiple doses a day' and third dose of 'once a day' gentamicin group). Trough levels were measured immediately before the administration of the dose on day three of therapy (fifth dose of 'multiple doses a day' and third dose of 'once a day' gentamicin group). Other outcome measured was cost of therapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-28 21:33:09 -0500" MODIFIED_BY="Shripada C Rao">
<P>Additional information and methodology were clarified by the authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BW = birth weight<BR/>h = hour<BR/>min = minute<BR/>vs = versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-11-21 16:03:14 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-11-21 15:58:59 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alsaedi--2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 15:58:59 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT. The controls were historical. 'Multiple doses a day' regimen was practised between November 1999 to October 2000 and 'once a day' gentamicin regimen was used between November 2000 and October 2002. Information from the first period was gathered from retrospective chart reviews.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-16 13:33:52 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alshaikh-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-16 13:33:52 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT. This was an Observational study comparing extended interval dosing to historical data of multiple dosing control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davies-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT. It was a retrospective study of neonates born in the last half of 1995 who received gentamicin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 15:59:25 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-English-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 15:59:25 -0500" MODIFIED_BY="[Empty name]">
<P>RCT. Loading dose of 8 mg/kg was used in 'once a day' gentamicin regimen whereas no loading dose was used in 'multiple doses a day' regimen.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-13 21:18:22 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fjalstad-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-13 21:18:22 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT. This was an observational study comparing 24 hourly, 36 hourly and 48 hourly dosing intervals.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 15:59:42 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gonzalez-Santacruz-M-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 15:59:42 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT. This was a retrospective study comparing the outcomes prior to and after implementation of the change in protocol to 'once a day' regimen.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 15:41:33 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hagen-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 15:41:33 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT. This was a retrospective comparative study of two periods involving change in regimen.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 16:00:11 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hansen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 16:00:11 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT. It was an audit of use of once-daily gentamicin for preterm and term infants for the period 31 March 1999 and 31 December 2000</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-13 21:20:26 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hiltron-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-13 21:20:26 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT. This was a retrospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 16:00:25 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoff-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 16:00:25 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT. This was a retrospective study comparing 24-hourly gentamicin to 48-hourly dose of gentamicin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 16:00:40 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hossain-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 16:00:40 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT. This was an observational study comparing 24-hourly and 48-hourly dosing intervals.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Isemann-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT. Compared the peak and trough concentrations of gentamicin in neonates after a standard dose or a loading dose on the first day of life.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 16:00:55 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaspers-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 16:00:55 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT. It was a retrospective and subsequently prospective descriptive study. Newborn infants were administered gentamicin twice a day in the year 1995 and their results were analysed retrospectively. Infants were administered gentamicin once a day in the year 1996.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 16:01:14 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krishnamoorthy-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 16:01:14 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT. This was a retrospective study comparing 24-hourly to 36-hourly dosing intervals.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lanao-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT. Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 16:01:26 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Low-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 16:01:26 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT. Observational study comparing 24-hourly to 36-hourly dosing intervals.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lundergan-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT. Information from controls were derived from retrospective chart review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 16:01:45 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinkova-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 16:01:45 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT. This was an observational study comparing 48-hourly , 36-hourly and 24-hourly dosing intervals.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 16:01:49 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mercado-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 16:01:49 -0500" MODIFIED_BY="[Empty name]">
<P>RCT. Compared 'once a day' to 'extended interval dosing of once in 48 hours' regimen of gentamicin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 16:02:04 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rastogi--2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 16:02:04 -0500" MODIFIED_BY="[Empty name]">
<P>RCT. 'Once a day' gentamicin regimen was compared to 'once in 48 hours' regimen of gentamicin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Semchuk-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT. Use of loading dose was compared to the regimen of no loading dose of gentamicin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 16:02:20 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Serane-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 16:02:20 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT. Only patients who received 'once a day' dosage were studied. There was no comparison group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Skopnik--1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT. It was an audit.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stickland-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT. It was an audit of the use of extended interval dosing method for gentamicin in neonates.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 16:02:32 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tantiprabha-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 16:02:32 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT. Only patients who received 'once a day' dosage were studied.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-08 17:21:10 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thingvoll-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-08 17:21:10 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT. This was an observational study. Participants were less than 28 weeks of gestation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 16:03:05 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tiwari-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 16:03:05 -0500" MODIFIED_BY="[Empty name]">
<P>Data from 0 to 12 year age group were published. Relevant data from neonatal population could not be derived from the published article. We made 3 attempts to obtain relevant data from the authors, but authors did not respond.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-21 16:03:14 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yeung-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-21 16:03:14 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT. This was an observational study including 'once a day' dosing with no comparison group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-12-05 01:34:05 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-12-05 01:32:33 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 14:13:47 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Agarwal-2002">
<DESCRIPTION>
<P>Computer generated numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-31 00:01:38 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chotigeat-2001">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 15:10:23 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hagan-2002">
<DESCRIPTION>
<P>Computer-generated numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 15:15:58 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hayani-1997">
<DESCRIPTION>
<P>"subjects were randomly assigned by clinical pharmacist investigators"; insufficient information about the sequence generation.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 15:29:38 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kosalaraksa-2004">
<DESCRIPTION>
<P>Computer-generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 15:32:58 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krishnan-1997">
<DESCRIPTION>
<P>Computer-generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-05 01:32:33 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Miron-2003">
<DESCRIPTION>
<P>Allocation based on the month of the year: single dose a day in January to March 1998; multiple doses a day in April/May1998.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 15:53:42 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Skopnik-1992">
<DESCRIPTION>
<P>Computer-generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 15:55:33 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solomon-1999">
<DESCRIPTION>
<P>"Babies in each groups were randomly assigned to receive injection gentamicin at a dose of..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 07:25:13 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thureen-1999">
<DESCRIPTION>
<P>Quasi-randomised trial; dose schedules were rotated on a monthly basis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-13 10:50:14 -0400" MODIFIED_BY="Colleen Ovelman" RESULT="UNKNOWN" STUDY_ID="STD-de-Alba-Romero-1998">
<DESCRIPTION>
<P>"Neonates were randomized to treatment with gentamicin 5mg/kg either once daily, or in twice divided doses."</P>
<P>The sequence generation process not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-12-05 01:32:59 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-27 07:24:37 -0500" MODIFIED_BY="Shripada C Rao" RESULT="YES" STUDY_ID="STD-Agarwal-2002">
<DESCRIPTION>
<P>Using sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 14:20:01 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chotigeat-2001">
<DESCRIPTION>
<P>Using sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 15:10:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hagan-2002">
<DESCRIPTION>
<P>Using sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-30 09:45:35 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hayani-1997">
<DESCRIPTION>
<P>Method of concealment has not been described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-27 08:24:09 -0500" MODIFIED_BY="Shripada C Rao" RESULT="YES" STUDY_ID="STD-Kosalaraksa-2004">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-10 03:25:55 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krishnan-1997">
<DESCRIPTION>
<P>Sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-05 01:32:59 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Miron-2003">
<DESCRIPTION>
<P>Allocation concealment was not achieved.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-10 03:35:14 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Skopnik-1992">
<DESCRIPTION>
<P>Insufficient information to allow a definite judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-02 02:08:42 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solomon-1999">
<DESCRIPTION>
<P>No method of concealment described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-10 03:38:24 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thureen-1999">
<DESCRIPTION>
<P>Allocation to a particular study group was open to investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-10 03:31:31 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Alba-Romero-1998">
<DESCRIPTION>
<P>Using sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-11-21 15:57:41 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-21 14:13:48 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Agarwal-2002">
<DESCRIPTION>
<P>Measurement of peak and trough level are unaffected by knowledge of types of dosing regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-28 10:29:01 -0500" MODIFIED_BY="Shripada C Rao" RESULT="YES" STUDY_ID="STD-Chotigeat-2001">
<DESCRIPTION>
<P>Outcome assessors were blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-21 15:10:14 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hagan-2002">
<DESCRIPTION>
<P>Lab personnel and the people performing hearing tests were blinded to the allocations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-21 15:16:18 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hayani-1997">
<DESCRIPTION>
<P>Outcomes measures such as peak/trough serum gentamicin levels and creatinine levels are not influenced by blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-06-10 03:23:33 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kosalaraksa-2004">
<DESCRIPTION>
<P>Outcome assessors were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-06-10 03:26:11 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krishnan-1997">
<DESCRIPTION>
<P>Outcome assessors were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-28 00:03:34 -0500" MODIFIED_BY="Shripada C Rao" RESULT="YES" STUDY_ID="STD-Miron-2003">
<DESCRIPTION>
<P>Lab personnel and statisticians were blinded to the intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-06-10 03:36:31 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Skopnik-1992">
<DESCRIPTION>
<P>Outcome measures unlikely to influence outcome measures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-06-10 03:37:24 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solomon-1999">
<DESCRIPTION>
<P>Outcome measurements unlikely to be effected by blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-21 15:57:41 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thureen-1999">
<DESCRIPTION>
<P>"Cost of labor was determined by time-in motion observations of gentamicin-associated tasks". Lack of blinding may have influenced cost-effectiveness analyses. But serum gentamicin concentration measurement unaffected by blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-28 00:31:57 -0500" MODIFIED_BY="Shripada C Rao" RESULT="YES" STUDY_ID="STD-de-Alba-Romero-1998">
<DESCRIPTION>
<P>Outcome assessors were blinded to the intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-12-05 01:33:43 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-21 14:13:49 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Agarwal-2002">
<DESCRIPTION>
<P>Only three infants were excluded after enrolment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 22:51:24 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chotigeat-2001">
<DESCRIPTION>
<P>All 54 eligible infants were included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-21 15:10:41 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hagan-2002">
<DESCRIPTION>
<P>Gentamicin levels were done in only 65 out of 100 infants. Otoacoustic emission test was done in only 59 infants. Serum creatinine levels were measured in 93 infants. Four infants were excluded because of withdrawal of parental consent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-21 15:16:39 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hayani-1997">
<DESCRIPTION>
<P>5 patients treated intravenously didn't complete study. 4 infants were discharged home before gentamicin concentration was due for measurement. 1 infant developed hypotension and shock and was excluded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-21 15:29:43 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kosalaraksa-2004">
<DESCRIPTION>
<P>Only 3 out of the 64 study infants did not have blood levels of gentamicin measured.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-30 23:13:12 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krishnan-1997">
<DESCRIPTION>
<P>All 18 neonates were included in the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-05 01:33:43 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miron-2003">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-02 00:31:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Skopnik-1992">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-04 09:55:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solomon-1999">
<DESCRIPTION>
<P>All 73 patients analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-04 09:55:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thureen-1999">
<DESCRIPTION>
<P>All 55 patients analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-27 08:27:51 -0500" MODIFIED_BY="Shripada C Rao" RESULT="NO" STUDY_ID="STD-de-Alba-Romero-1998">
<DESCRIPTION>
<P>Only 65 out of the 80 completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-12-05 01:34:05 -0500" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-10 03:16:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Agarwal-2002">
<DESCRIPTION>
<P>Predetermined outcome measures reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 22:51:37 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chotigeat-2001">
<DESCRIPTION>
<P>Included all prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-05 01:31:03 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hagan-2002">
<DESCRIPTION>
<P>Information available only in abstract form. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-30 10:26:28 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hayani-1997">
<DESCRIPTION>
<P>All expected outcomes have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 15:30:10 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kosalaraksa-2004">
<DESCRIPTION>
<P>"serum creatinine was measured on days 0, 3 and 7 or discontinuation day": statistical method to compare was not pre-specified.</P>
<P>"The authors evaluated the clinical response using inclusion point of "improvement within 72 hours of treatment": method to define "improvement within 72 hour of treatment" not pre-defined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 15:33:10 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Krishnan-1997">
<DESCRIPTION>
<P>"There was no nephrotoxicity in either groups at the end of therapy." There was no pre-specified analysis method to measure nephrotoxicity in the methodology.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-05 01:34:05 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miron-2003">
<DESCRIPTION>
<P>All prespecified outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 15:53:53 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Skopnik-1992">
<DESCRIPTION>
<P>All prespecified outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-10 03:37:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solomon-1999">
<DESCRIPTION>
<P>Pre-specified primary outcomes have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 15:57:54 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thureen-1999">
<DESCRIPTION>
<P>All prespecified primary outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-03 07:46:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Alba-Romero-1998">
<DESCRIPTION>
<P>"Clinical efficacy was determined in both groups by clinical evaluation by customary evaluations" It is unclear how this was done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-12-05 01:31:19 -0500" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-10 03:16:24 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Agarwal-2002">
<DESCRIPTION>
<P>Appear to be free of other source of biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-21 14:20:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chotigeat-2001">
<DESCRIPTION>
<P>Appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-05 01:31:19 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hagan-2002">
<DESCRIPTION>
<P>Information available only in abstract form.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-31 01:05:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hayani-1997">
<DESCRIPTION>
<P>Appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-10 03:24:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kosalaraksa-2004">
<DESCRIPTION>
<P>Appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-10 03:29:55 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krishnan-1997">
<DESCRIPTION>
<P>Appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-06 22:09:07 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miron-2003">
<DESCRIPTION>
<P>Appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-10 03:36:27 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Skopnik-1992">
<DESCRIPTION>
<P>Appears to be free of other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-10 03:38:04 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solomon-1999">
<DESCRIPTION>
<P>Appears to be free of other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-16 13:33:47 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thureen-1999">
<DESCRIPTION>
<P>Appears to be free of other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-10 03:34:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Alba-Romero-1998">
<DESCRIPTION>
<P>Appears to be free of other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-11-22 18:20:53 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-11-22 18:20:53 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-04-11 08:13:10 -0400" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>One dose per day compared with multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: neonates</B> with suspected or proven sepsis</P>
<P>
<B>Settings: neonatal intensive care units </B>
</P>
<P>
<B>Intervention: one dose per day gentamicin</B>
</P>
<P>
<B>Comparison: multiple doses per day gentamicin</B>
</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Multiple doses per day of gentamicin</P>
</TH>
<TH VALIGN="TOP">
<P>One dose per day gentamicin</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Clearance of proven </B>
</P>
<P>
<B>sepsis</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>Actual risk: 17 per 17</B>
</P>
<P/>
<P>
<B>(1000 per 1000)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Actual risk: 20 per 20</B>
</P>
<P/>
<P>
<B>(1000 per 1000)</B>
</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1</B>(0.84 to 1.19)</P>
</TD>
<TD VALIGN="TOP">
<P>37</P>
<P>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Very small sample size, high risk of bias in the domain of completeness of follow-up in 2 studies, high risk of bias for random sequence generation and allocation concealment in one study.</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Failure to </B>
</P>
<P>
<B>achieve peak levels of at least 5 microgram/ml</B>
</P>
<P>(measured 0.5 to one hour after administration of any dose of gentamicin)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Actual risk: 35 per 214</B>
<BR/>
</P>
<P>
<B>(164 per 1000)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Actual risk: </B>
</P>
<P>
<B>6 per 208</B>
</P>
<P>
<B>(29 per 1000)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.22</B> <B>(0.11 to 0.47)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>422</P>
<P>(9 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Moderate sample size, high risk of selection bias in two studies; high risk of attrition bias in 3 studies.</P>
<P>Narrow CIs around the effect size, very low P value for effect size</P>
<P>estimate, no statistical heterogeneity</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Nephrotoxicity</B>
</P>
<P>(End of study period or before discharge)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>348</P>
<P>(8 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>None of the study infants developed nephrotoxicity.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Ototoxicity</B>
</P>
<P>(End of study period or before discharge)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Actual risk: 1 per 111</B>
</P>
<P/>
<P>
<B>(9 per 1000)</B>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Actual risk: </B>
</P>
<P>
<B>2 per 103</B>
</P>
<P/>
<P>
<B>(19 per 1000)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.69</B> ( <B>0.18 to 16.25 )</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>214</P>
<P>(5 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Small sample size. Unclear risk of selection bias and reporting bias and high risk of attrition bias in the included studies.</P>
<P>Wide CIs around the effect size, P value for effect size is greater than 0.05.</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Failure to </B>
</P>
<P>
<B>achieve trough levels of </B>&#8804;<B> 2 microgram/ml</B>
</P>
<P>(measured within one hour prior to the administration of gentamicin on any day except the initial dose)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Actual risk: 92 per 259</B>
</P>
<P/>
<P/>
<P>
<B>(355 per 1000)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Actual risk: 31/244</B>
</P>
<P/>
<P>
<B>(127 per 1000)</B>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.38 </B>
</P>
<P>
<B>(</B>0.27 to 0.55)</P>
</TD>
<TD VALIGN="TOP">
<P>503 (11 studies)</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Moderate sample size, high risk of selection bias in 2 studies, high risk of attrition bias in 3 studies, high risk of reporting bias in 2 studies.</P>
<P>Narrow CIs around the effect size, very low P value for effect size estimate, moderate heterogeneity</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk Ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-11-22 18:39:58 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-11-22 18:39:58 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>All studies comparing 'once a day' versus 'multiple doses a day' regimen</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.18699121384251274" CI_START="-0.18699121384251274" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.7281787991819956" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-11-22 18:35:52 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="17" WEIGHT="99.99999999999999" Z="0.0">
<NAME>Clearance of proven sepsis</NAME>
<GROUP_LABEL_1>Once a day</GROUP_LABEL_1>
<GROUP_LABEL_2>Multiple doses a day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.12458092900472632" CI_START="-0.12458092900472632" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0635628664543863" STUDY_ID="STD-de-Alba-Romero-1998" TOTAL_1="14" TOTAL_2="15" VAR="0.004040237991898148" WEIGHT="84.45040214477211"/>
<DICH_DATA CI_END="0.639565654391803" CI_START="-0.639565654391803" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.3263150034575203" STUDY_ID="STD-Hagan-2002" TOTAL_1="5" TOTAL_2="1" VAR="0.10648148148148148" WEIGHT="9.718498659517428"/>
<DICH_DATA CI_END="0.8486893005571289" CI_START="-0.8486893005571289" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.4330127018922193" STUDY_ID="STD-Miron-2003" TOTAL_1="1" TOTAL_2="1" VAR="0.1875" WEIGHT="5.831099195710456"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.3471904439658315" CI_END="0.4653052303910344" CI_START="0.10775279630970902" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22391502788372053" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.3322620656330823" LOG_CI_START="-0.9675714505768052" LOG_EFFECT_SIZE="-0.6499167581049438" METHOD="MH" MODIFIED="2016-11-22 18:36:23 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6176737908742155" P_Q="1.0" P_Z="6.0704079126977255E-5" Q="0.0" RANDOM="NO" SCALE="272.9293152019625" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="208" TOTAL_2="214" WEIGHT="100.0" Z="4.010057049440745">
<NAME>Failure to achieve peak levels of at least 5 microgram/ml</NAME>
<GROUP_LABEL_1>Once a day</GROUP_LABEL_1>
<GROUP_LABEL_2>Multiple doses a day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ODD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MDD</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.102435408890784" CI_START="0.015050422270841747" EFFECT_SIZE="0.3492063492063492" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9086155776031525" LOG_CI_START="-1.8224513148659038" LOG_EFFECT_SIZE="-0.4569178686313755" ORDER="4" O_E="0.0" SE="1.6042422116354729" STUDY_ID="STD-Agarwal-2002" TOTAL_1="20" TOTAL_2="21" VAR="2.5735930735930737" WEIGHT="4.033452992810674"/>
<DICH_DATA CI_END="1.1121861349790028" CI_START="0.0039961336548475805" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.04617747666100038" LOG_CI_START="-2.398359994772363" LOG_EFFECT_SIZE="-1.1760912590556813" ORDER="5" O_E="0.0" SE="1.435933411375598" STUDY_ID="STD-Chotigeat-2001" TOTAL_1="27" TOTAL_2="27" VAR="2.061904761904762" WEIGHT="20.647437939387974"/>
<DICH_DATA CI_END="1.088126695349167" CI_START="0.003847760769925011" EFFECT_SIZE="0.06470588235294118" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.03667946511180465" LOG_CI_START="-2.414791937551902" LOG_EFFECT_SIZE="-1.1890562362200487" ORDER="10" O_E="0.0" SE="1.440006436903815" STUDY_ID="STD-de-Alba-Romero-1998" TOTAL_1="33" TOTAL_2="32" VAR="2.073618538324421" WEIGHT="20.95560865490123"/>
<DICH_DATA CI_END="2.1839823287055524" CI_START="0.03043398487369869" EFFECT_SIZE="0.2578125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3392491200323722" LOG_CI_START="-1.5166411795723338" LOG_EFFECT_SIZE="-0.5886960297699809" ORDER="6" O_E="0.0" SE="1.0901591487929503" STUDY_ID="STD-Hagan-2002" TOTAL_1="32" TOTAL_2="33" VAR="1.1884469696969697" WEIGHT="10.842552025606814"/>
<DICH_DATA CI_END="5.057696031838569" CI_START="0.014059981197656286" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7039527246402436" LOG_CI_START="-1.8520152600956814" LOG_EFFECT_SIZE="-0.5740312677277188" ORDER="7" O_E="0.0" SE="1.5013882464794597" STUDY_ID="STD-Hayani-1997" TOTAL_1="11" TOTAL_2="15" VAR="2.2541666666666664" WEIGHT="5.899267982682279"/>
<DICH_DATA CI_END="20.241672484853872" CI_START="0.18506859142095836" EFFECT_SIZE="1.935483870967742" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3062463935894317" LOG_CI_START="-0.7326672804906896" LOG_EFFECT_SIZE="0.28678955654937094" ORDER="8" O_E="0.0" SE="1.1976679849401242" STUDY_ID="STD-Kosalaraksa-2004" TOTAL_1="31" TOTAL_2="30" VAR="1.4344086021505376" WEIGHT="2.7981227371411026"/>
<DICH_DATA CI_END="0.7448265212893319" CI_START="0.049758428544405375" EFFECT_SIZE="0.1925133689839572" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.12794486768119306" LOG_CI_START="-1.3031333438572306" LOG_EFFECT_SIZE="-0.7155391057692118" ORDER="9" O_E="0.0" SE="0.6903115281825812" STUDY_ID="STD-Miron-2003" TOTAL_1="17" TOTAL_2="18" VAR="0.47653000594177064" WEIGHT="29.417683006975626"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11" O_E="0.0" SE="0.0" STUDY_ID="STD-Skopnik-1992" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.391052854685162" CI_START="0.049871789665905775" EFFECT_SIZE="0.5185185185185185" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7316735897372958" LOG_CI_START="-1.3021450466987943" LOG_EFFECT_SIZE="-0.2852357284807493" ORDER="12" O_E="0.0" SE="1.1946751346071773" STUDY_ID="STD-Thureen-1999" TOTAL_1="27" TOTAL_2="28" VAR="1.4272486772486772" WEIGHT="5.405874660494306"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.670997084201163" CI_END="0.5462575798582643" CI_START="0.26957257117362315" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.38373957357232924" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="92" I2="42.56906595258435" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.26260252371895226" LOG_CI_START="-0.5693242990578918" LOG_EFFECT_SIZE="-0.415963411388422" METHOD="MH" MODIFIED="2016-11-22 18:37:17 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.07407813328284552" P_Q="1.0" P_Z="1.060472183873141E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="244" TOTAL_2="259" WEIGHT="100.00000000000001" Z="5.316044511719566">
<NAME>Failure to achieve trough levels of &lt;= 2 microgram/ml</NAME>
<GROUP_LABEL_1>Once a day</GROUP_LABEL_1>
<GROUP_LABEL_2>Multiple doses a day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ODD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MDD</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0323585621906504" CI_START="0.006666861327996716" EFFECT_SIZE="0.1164021164021164" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.30800033148751804" LOG_CI_START="-2.176078578189594" LOG_EFFECT_SIZE="-0.9340391233510379" ORDER="13" O_E="0.0" SE="1.459160247933252" STUDY_ID="STD-Agarwal-2002" TOTAL_1="20" TOTAL_2="21" VAR="2.1291486291486295" WEIGHT="4.928725244278787"/>
<DICH_DATA CI_END="3.9804702774957645" CI_START="0.010049063857139322" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5999343853540574" LOG_CI_START="-1.9978743940260948" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="14" O_E="0.0" SE="1.5259657363687524" STUDY_ID="STD-Chotigeat-2001" TOTAL_1="27" TOTAL_2="27" VAR="2.3285714285714287" WEIGHT="2.8033754696294695"/>
<DICH_DATA CI_END="1.2436373736876092" CI_START="0.28633311720834753" EFFECT_SIZE="0.5967365967365967" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.09469376494915796" LOG_CI_START="-0.5431284186949074" LOG_EFFECT_SIZE="-0.22421732687287468" ORDER="20" O_E="0.0" SE="0.37465990794325277" STUDY_ID="STD-de-Alba-Romero-1998" TOTAL_1="33" TOTAL_2="32" VAR="0.14037004662004662" WEIGHT="14.801822479643597"/>
<DICH_DATA CI_END="5.576289364307802" CI_START="0.5840616868813687" EFFECT_SIZE="1.8046875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7463453020450231" LOG_CI_START="-0.23354128155647128" LOG_EFFECT_SIZE="0.25640201024427595" ORDER="15" O_E="0.0" SE="0.5755902297243348" STUDY_ID="STD-Hagan-2002" TOTAL_1="32" TOTAL_2="33" VAR="0.3313041125541125" WEIGHT="4.416394586000887"/>
<DICH_DATA CI_END="1.627830610839608" CI_START="0.03173112252468441" EFFECT_SIZE="0.22727272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.21160921099235333" LOG_CI_START="-1.4985145639647284" LOG_EFFECT_SIZE="-0.6434526764861874" ORDER="16" O_E="0.0" SE="1.0045351706590016" STUDY_ID="STD-Hayani-1997" TOTAL_1="11" TOTAL_2="15" VAR="1.0090909090909093" WEIGHT="5.693008646016768"/>
<DICH_DATA CI_END="0.8822688078416863" CI_START="0.20818311579787066" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="20" LOG_CI_END="-0.054399074759098096" LOG_CI_START="-0.6815544958300908" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="17" O_E="0.0" SE="0.36839419880650365" STUDY_ID="STD-Kosalaraksa-2004" TOTAL_1="21" TOTAL_2="30" VAR="0.13571428571428573" WEIGHT="18.4692972116765"/>
<DICH_DATA CI_END="0.7873552033085051" CI_START="0.0035182127340405572" EFFECT_SIZE="0.05263157894736842" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.10382929809209303" LOG_CI_START="-2.4536779038135648" LOG_EFFECT_SIZE="-1.278753600952829" ORDER="18" O_E="0.0" SE="1.3803127029389886" STUDY_ID="STD-Krishnan-1997" TOTAL_1="9" TOTAL_2="9" VAR="1.9052631578947365" WEIGHT="10.652826784591984"/>
<DICH_DATA CI_END="0.9608812445546415" CI_START="0.10500741330007399" EFFECT_SIZE="0.3176470588235294" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="-0.017330283529742172" LOG_CI_START="-0.9787800395808689" LOG_EFFECT_SIZE="-0.49805516155530544" ORDER="19" O_E="0.0" SE="0.5647603459574805" STUDY_ID="STD-Miron-2003" TOTAL_1="17" TOTAL_2="18" VAR="0.31895424836601305" WEIGHT="10.893116110560223"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21" O_E="0.0" SE="0.0" STUDY_ID="STD-Skopnik-1992" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.438954102255631" CI_START="0.23684112347620087" EFFECT_SIZE="0.5837837837837838" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.1580469416398661" LOG_CI_START="-0.6255428874719943" LOG_EFFECT_SIZE="-0.23374797291606408" ORDER="22" O_E="0.0" SE="0.4602845444525178" STUDY_ID="STD-Solomon-1999" TOTAL_1="37" TOTAL_2="36" VAR="0.21186186186186184" WEIGHT="11.367111493292095"/>
<DICH_DATA CI_END="0.5704952806939496" CI_START="0.002235794488133371" EFFECT_SIZE="0.03571428571428571" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="14" LOG_CI_END="-0.24374794384358145" LOG_CI_START="-2.650568118840857" LOG_EFFECT_SIZE="-1.4471580313422192" ORDER="23" O_E="0.0" SE="1.4137780847454116" STUDY_ID="STD-Thureen-1999" TOTAL_1="27" TOTAL_2="28" VAR="1.9987684729064041" WEIGHT="15.974321974309678"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.252962493069354" CI_START="0.17620820368379145" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6923076923076923" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.2109325331382284" LOG_CI_START="-0.7539738761074893" LOG_EFFECT_SIZE="0.22847932851536945" METHOD="MH" MODIFIED="2016-11-22 18:37:58 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6485271556957816" Q="0.0" RANDOM="NO" SCALE="16.3" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="111" WEIGHT="100.00000000000001" Z="0.4558092466846032">
<NAME>Ototoxicity</NAME>
<GROUP_LABEL_1>Once a day</GROUP_LABEL_1>
<GROUP_LABEL_2>Multiple doses a day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ODD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MDD</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24" O_E="0.0" SE="0.0" STUDY_ID="STD-Agarwal-2002" TOTAL_1="20" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.252962493069354" CI_START="0.17620820368379145" EFFECT_SIZE="1.6923076923076923" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2109325331382284" LOG_CI_START="-0.7539738761074893" LOG_EFFECT_SIZE="0.22847932851536945" ORDER="27" O_E="0.0" SE="1.1541957512345262" STUDY_ID="STD-de-Alba-Romero-1998" TOTAL_1="13" TOTAL_2="11" VAR="1.3321678321678323" WEIGHT="100.00000000000001"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25" O_E="0.0" SE="0.0" STUDY_ID="STD-Hagan-2002" TOTAL_1="26" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28" O_E="0.0" SE="0.0" STUDY_ID="STD-Miron-2003" TOTAL_1="17" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="26" O_E="0.0" SE="0.0" STUDY_ID="STD-Thureen-1999" TOTAL_1="27" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-11-22 18:39:14 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="172" TOTAL_2="176" WEIGHT="0.0" Z="0.0">
<NAME>Nephrotoxicity</NAME>
<GROUP_LABEL_1>Once a day</GROUP_LABEL_1>
<GROUP_LABEL_2>Multiple doses a day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ODD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MDD</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="29" O_E="0.0" SE="0.0" STUDY_ID="STD-Agarwal-2002" TOTAL_1="20" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30" O_E="0.0" SE="0.0" STUDY_ID="STD-Chotigeat-2001" TOTAL_1="27" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="31" O_E="0.0" SE="0.0" STUDY_ID="STD-Hagan-2002" TOTAL_1="46" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="32" O_E="0.0" SE="0.0" STUDY_ID="STD-Hayani-1997" TOTAL_1="11" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosalaraksa-2004" TOTAL_1="33" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="34" O_E="0.0" SE="0.0" STUDY_ID="STD-Krishnan-1997" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="36" O_E="0.0" SE="0.0" STUDY_ID="STD-Miron-2003" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="35" O_E="0.0" SE="0.0" STUDY_ID="STD-Skopnik-1992" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.18699121384251274" CI_START="-0.18699121384251274" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.7281787991819956" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-11-22 18:39:58 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="17" WEIGHT="99.99999999999999" Z="0.0">
<NAME>Treatment failure</NAME>
<GROUP_LABEL_1>Once a day</GROUP_LABEL_1>
<GROUP_LABEL_2>Multiple doses a day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.12458092900472632" CI_START="-0.12458092900472632" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="39" O_E="0.0" SE="0.0635628664543863" STUDY_ID="STD-de-Alba-Romero-1998" TOTAL_1="14" TOTAL_2="15" VAR="0.004040237991898148" WEIGHT="84.45040214477211"/>
<DICH_DATA CI_END="0.639565654391803" CI_START="-0.639565654391803" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="37" O_E="0.0" SE="0.3263150034575203" STUDY_ID="STD-Hagan-2002" TOTAL_1="5" TOTAL_2="1" VAR="0.10648148148148148" WEIGHT="9.718498659517428"/>
<DICH_DATA CI_END="0.8486893005571289" CI_START="-0.8486893005571289" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38" O_E="0.0" SE="0.4330127018922193" STUDY_ID="STD-Miron-2003" TOTAL_1="1" TOTAL_2="1" VAR="0.1875" WEIGHT="5.831099195710456"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="34.210751085630115" CI_END="2.89021230476743" CI_START="2.2608282216780378" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="2.575520263222734" ESTIMABLE="YES" I2="73.69248053784952" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2008-10-16 09:10:44 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="8.203439180864969E-5" P_Q="1.0" P_Z="6.624445365823041E-58" Q="0.0" RANDOM="NO" SCALE="6.469839238073396" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="223" UNITS="" WEIGHT="100.0" Z="16.040847212377667">
<NAME>Actual peak levels (µg/ml)</NAME>
<GROUP_LABEL_1>Once a day</GROUP_LABEL_1>
<GROUP_LABEL_2>Multiple doses a day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MDD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ODD</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.908396756577038" CI_START="1.2916032434229627" EFFECT_SIZE="2.1000000000000005" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="6.8" ORDER="40" SD_1="1.5" SD_2="1.1" SE="0.4124549037398484" STUDY_ID="STD-Agarwal-2002" TOTAL_1="20" TOTAL_2="21" WEIGHT="15.153829445644416"/>
<CONT_DATA CI_END="3.8228435971894053" CI_START="2.137156402810594" EFFECT_SIZE="2.9799999999999995" ESTIMABLE="YES" MEAN_1="8.92" MEAN_2="5.94" ORDER="41" SD_1="1.59" SD_2="1.57" SE="0.43003014536881706" STUDY_ID="STD-Chotigeat-2001" TOTAL_1="27" TOTAL_2="27" WEIGHT="13.940473841981117"/>
<CONT_DATA CI_END="3.9023312109558583" CI_START="2.297668789044141" EFFECT_SIZE="3.0999999999999996" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="6.4" ORDER="46" SD_1="1.7" SD_2="1.6" SE="0.40936018074033237" STUDY_ID="STD-de-Alba-Romero-1998" TOTAL_1="33" TOTAL_2="32" WEIGHT="15.383818461384946"/>
<CONT_DATA CI_END="5.863184613361897" CI_START="2.7368153866381046" EFFECT_SIZE="4.300000000000001" ESTIMABLE="YES" MEAN_1="11.4" MEAN_2="7.1" ORDER="42" SD_1="2.2" SD_2="4.0" SE="0.7975578253948016" STUDY_ID="STD-Hagan-2002" TOTAL_1="32" TOTAL_2="33" WEIGHT="4.0527608451835295"/>
<CONT_DATA CI_END="5.504592511739281" CI_START="2.6954074882607184" EFFECT_SIZE="4.1" ESTIMABLE="YES" MEAN_1="10.7" MEAN_2="6.6" ORDER="43" SD_1="2.1" SD_2="1.3" SE="0.7166420009849811" STUDY_ID="STD-Hayani-1997" TOTAL_1="11" TOTAL_2="15" WEIGHT="5.019619783541349"/>
<CONT_DATA CI_END="3.5757181301886085" CI_START="1.0242818698113911" EFFECT_SIZE="2.3" ESTIMABLE="YES" MEAN_1="10.1" MEAN_2="7.8" ORDER="44" SD_1="3.0" SD_2="2.0" SE="0.6508885572649857" STUDY_ID="STD-Kosalaraksa-2004" TOTAL_1="31" TOTAL_2="30" WEIGHT="6.085020763348457"/>
<CONT_DATA CI_END="2.648360181468081" CI_START="-0.4283601814680822" EFFECT_SIZE="1.1099999999999994" ESTIMABLE="YES" MEAN_1="6.56" MEAN_2="5.45" ORDER="45" SD_1="1.66" SD_2="1.67" SE="0.7848920661820679" STUDY_ID="STD-Krishnan-1997" TOTAL_1="9" TOTAL_2="9" WEIGHT="4.184614536508355"/>
<CONT_DATA CI_END="6.356249625753322" CI_START="1.643750374246678" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="9.9" MEAN_2="5.9" ORDER="49" SD_1="4.6" SD_2="1.9" SE="1.2021902669330244" STUDY_ID="STD-Miron-2003" TOTAL_1="17" TOTAL_2="18" WEIGHT="1.783729203212662"/>
<CONT_DATA CI_END="3.993724918717964" CI_START="2.406275081282038" EFFECT_SIZE="3.200000000000001" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="5.1" ORDER="47" SD_1="1.0" SD_2="0.8" SE="0.4049691346263318" STUDY_ID="STD-Skopnik-1992" TOTAL_1="10" TOTAL_2="10" WEIGHT="15.719238006551874"/>
<CONT_DATA CI_END="1.9281710690078189" CI_START="0.4718289309921814" EFFECT_SIZE="1.2000000000000002" ESTIMABLE="YES" MEAN_1="7.9" MEAN_2="6.7" ORDER="48" SD_1="1.6" SD_2="1.1" SE="0.37152267835099995" STUDY_ID="STD-Thureen-1999" TOTAL_1="27" TOTAL_2="28" WEIGHT="18.676895112643294"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="27.260080305939045" CI_END="-0.4448137933237117" CI_START="-0.6874160813320115" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5661149373278616" ESTIMABLE="YES" I2="70.65305784056304" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2008-10-16 09:10:53 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="6.37460988035965E-4" P_Q="1.0" P_Z="5.843245152290197E-20" Q="0.0" RANDOM="NO" SCALE="1.627898996075201" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="223" UNITS="" WEIGHT="100.0" Z="9.14719228233164">
<NAME>Actual trough levels (µg/ml).</NAME>
<GROUP_LABEL_1>Once a day</GROUP_LABEL_1>
<GROUP_LABEL_2>Multiple doses a day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ODD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MDD</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4116596724763402" CI_START="-0.98834032752366" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="1.6" ORDER="50" SD_1="0.3" SD_2="0.6" SE="0.14711511527663343" STUDY_ID="STD-Agarwal-2002" TOTAL_1="20" TOTAL_2="21" WEIGHT="17.69778923211167"/>
<CONT_DATA CI_END="-0.3128670671184032" CI_START="-0.7671329328815967" EFFECT_SIZE="-0.5399999999999999" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="1.44" ORDER="51" SD_1="0.35" SD_2="0.49" SE="0.11588627886695486" STUDY_ID="STD-Chotigeat-2001" TOTAL_1="27" TOTAL_2="27" WEIGHT="28.52131701755291"/>
<CONT_DATA CI_END="-0.37918480155554457" CI_START="-1.220815198444456" EFFECT_SIZE="-0.8000000000000003" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="2.2" ORDER="56" SD_1="0.7" SD_2="1.0" SE="0.21470557712477997" STUDY_ID="STD-de-Alba-Romero-1998" TOTAL_1="33" TOTAL_2="32" WEIGHT="8.308965584311991"/>
<CONT_DATA CI_END="0.9740903288151599" CI_START="-0.17409032881515962" EFFECT_SIZE="0.40000000000000013" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.4" ORDER="52" SD_1="1.4" SD_2="0.9" SE="0.2929086112517939" STUDY_ID="STD-Hagan-2002" TOTAL_1="32" TOTAL_2="33" WEIGHT="4.4644640689217185"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="1.7" MEAN_2="1.7" ORDER="53" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Hayani-1997" TOTAL_1="11" TOTAL_2="15" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.42178651397008826" CI_START="-1.5782134860299117" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="2.6" ORDER="54" SD_1="1.1" SD_2="1.2" SE="0.29501230154777636" STUDY_ID="STD-Kosalaraksa-2004" TOTAL_1="31" TOTAL_2="30" WEIGHT="4.401020180483557"/>
<CONT_DATA CI_END="-0.19766749699466846" CI_START="-1.402332503005331" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="1.96" MEAN_2="2.76" ORDER="55" SD_1="0.6" SD_2="0.7" SE="0.3073181485764296" STUDY_ID="STD-Krishnan-1997" TOTAL_1="9" TOTAL_2="9" WEIGHT="4.055619431593994"/>
<CONT_DATA CI_END="-0.35885743706842205" CI_START="-1.3411425629315776" EFFECT_SIZE="-0.8499999999999999" ESTIMABLE="YES" MEAN_1="1.55" MEAN_2="2.4" ORDER="59" SD_1="0.55" SD_2="0.9" SE="0.2505875448761547" STUDY_ID="STD-Miron-2003" TOTAL_1="17" TOTAL_2="18" WEIGHT="6.099786706899111"/>
<CONT_DATA CI_END="0.07718076486993569" CI_START="-0.4771807648699356" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.0" ORDER="57" SD_1="0.2" SD_2="0.4" SE="0.14142135623730953" STUDY_ID="STD-Skopnik-1992" TOTAL_1="10" TOTAL_2="10" WEIGHT="19.151536204749416"/>
<CONT_DATA CI_END="-0.5510289962684514" CI_START="-1.4489710037315486" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="2.0" ORDER="58" SD_1="0.5" SD_2="1.1" SE="0.22907104787280513" STUDY_ID="STD-Thureen-1999" TOTAL_1="27" TOTAL_2="28" WEIGHT="7.299501573375627"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-12-05 01:34:06 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-11-21 16:04:19 -0500" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram: review update</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAAOtCAYAAAAVfQRCAAB740lEQVR42uy9D2SV7x///yFJksTk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-12-05 01:34:06 -0500" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUUAAAJkCAIAAAAJDqQEAAAdL0lEQVR42u3dv27lxBvG8SMhIYoU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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-12-05 01:34:06 -0500" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 All studies comparing 'once a day' versus 'multiple doses a day' regimen, outcome: 1.1 Clearance of proven sepsis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAy4AAACwCAMAAADe6co3AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-12-05 01:34:06 -0500" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 All studies comparing 'once a day' versus 'multiple doses a day' regimen, outcome: 1.2 Failure to achieve peak levels of at least 5 microgram/ml.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAysAAAEQCAMAAACHqxspAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-12-05 01:34:06 -0500" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 All studies comparing 'once a day' versus 'multiple doses a day' regimen, outcome: 1.3 Failure to achieve trough levels of &#8804; 2 microgram/ml.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAysAAAEwCAMAAACABx4fAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2016-12-05 01:34:06 -0500" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.05" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 All studies comparing 'once a day' versus 'multiple doses a day' regimen, outcome: 1.5 Nephrotoxicity.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxwAAAEACAMAAAAOUoDzAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-10-11 05:37:13 -0400" MODIFIED_BY="Shripada C Rao"/>
<APPENDICES MODIFIED="2016-11-21 16:04:59 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-11-21 16:04:59 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-05-13 11:05:33 -0400" MODIFIED_BY="Colleen Ovelman">Risk of Bias tool</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-21 16:04:59 -0500" MODIFIED_BY="[Empty name]">
<P>The following items were entered into the 'Risk of bias' table:</P>
<P>(1) Sequence generation (checking for possible selection bias). Was the allocation sequence adequately generated?</P>
<P>For each included study, we categorized the method used to generate the allocation sequence as:</P>
<P>- adequate (low risk of bias) (any truly random process e.g. random number table; computer random number generator);</P>
<P>- inadequate (high risk of bias) (any non random process e.g. odd or even date of birth; hospital or clinic record number);</P>
<P>- unclear risk of bias.</P>
<P>(2) Allocation concealment (checking for possible selection bias). Was allocation adequately concealed?</P>
<P>For each included study, we categorized the method used to conceal the allocation sequence as:</P>
<P>- adequate (low risk of bias) (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</P>
<P>- inadequate (high risk of bias) (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</P>
<P>- unclear risk of bias.</P>
<P>(3) Blinding (checking for possible performance bias). Was knowledge of the allocated intervention adequately prevented during the study? At study entry? At the time of outcome assessment?</P>
<P>For each included study, we categorized the methods used to blind study participants and personnel from knowledge of which intervention a participant received. Blinding was assessed separately for different outcomes or classes of outcomes. We categorized the methods as:</P>
<P>- adequate (low risk of bias), inadequate (high risk of bias) or unclear risk of bias for participants;</P>
<P>- adequate (low risk of bias), inadequate (high risk of bias) or unclear risk of bias for personnel;</P>
<P>- adequate (low risk of bias), inadequate (high risk of bias) or unclear risk of bias for outcome assessors.</P>
<P>In some situations there may be partial blinding e.g. where outcomes are self-reported by unblinded participants but they are recorded by blinded personnel without knowledge of group assignment. Where needed &#8220;partial&#8221; was added to the list of options for assessing quality of blinding.</P>
<P>(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations). Were incomplete outcome data adequately addressed?</P>
<P>For each included study and for each outcome, we described the completeness of data including attrition and exclusions from the analysis. We noted whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported or supplied by the trial authors, we re-included missing data in the analyses. We categorized the methods as:</P>
<P>- adequate (low risk of bias) (&lt; 20% missing data);</P>
<P>- inadequate (high risk of bias) (<U>&gt;</U> 20% missing data):</P>
<P>- unclear risk of bias.</P>
<P>(5) Selective reporting bias. Are reports of the study free of suggestion of selective outcome reporting?</P>
<P>For each included study, we described how we investigated the possibility of selective outcome reporting bias and what we found. We assessed the methods as:</P>
<P>- adequate (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</P>
<P>- inadequate (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</P>
<P>- unclear risk of bias.</P>
<P>(6) Other sources of bias. Was the study apparently free of other problems that could put it at a high risk of bias?</P>
<P>For each included study, we described any important concerns we had about other possible sources of bias (for example, whether there was a potential source of bias related to the specific study design or whether the trial was stopped early due to some data-dependent process). We assessed whether each study was free of other problems that could put it at risk of bias as:</P>
<P>- yes; no; or unclear.</P>
<P>If needed, we planned to explore the impact of the level of bias through undertaking sensitivity analyses.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-10-11 05:37:13 -0400" MODIFIED_BY="Shripada C Rao">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;11 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;11 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="125">
<FLOWCHARTBOX TEXT="&lt;p&gt;11 studies included in previous version of review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 NEW studies included&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;9 of full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;96 of records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;96 of records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;144 of records identified through database searching&lt;/p&gt;&lt;p&gt;MEDLINE (1966 to 29 April 2016), Embase (1980 to 29 April 2016), CENTRAL, the Cochrane Library, April 2016&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;9 of additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;87 of records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;9 of full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>